<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article article-type="research-article" dtd-version="1.2" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">69729</article-id><article-id pub-id-type="doi">10.7554/eLife.69729</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group></article-categories><title-group><article-title><italic>Rpl24<sup>Bst</sup></italic> mutation suppresses colorectal cancer by promoting eEF2 phosphorylation via eEF2K</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-44507"><name><surname>Knight</surname><given-names>John RP</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8771-5484</contrib-id><email>j.knight@beatson.gla.ac.uk</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-236037"><name><surname>Vlahov</surname><given-names>Nikola</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-236038"><name><surname>Gay</surname><given-names>David M</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="pa1">†</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-16631"><name><surname>Ridgway</surname><given-names>Rachel A</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-151183"><name><surname>Faller</surname><given-names>William Liam</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="pa2">‡</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-178764"><name><surname>Proud</surname><given-names>Christopher</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-175743"><name><surname>Mallucci</surname><given-names>Giovanna R</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-4445"><name><surname>von der Haar</surname><given-names>Tobias</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6031-9254</contrib-id><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-44515"><name><surname>Smales</surname><given-names>Christopher Mark</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-174495"><name><surname>Willis</surname><given-names>Anne E</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1470-8531</contrib-id><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-217017"><name><surname>Sansom</surname><given-names>Owen J</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9540-3010</contrib-id><email>o.sansom@beatson.gla.ac.uk</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>CRUK Beatson Institute, Garscube Estate</institution><addr-line><named-content content-type="city">Glasgow</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff2"><label>2</label><institution>Institute of Cancer Sciences, University of Glasgow</institution><addr-line><named-content content-type="city">Glasgow</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff3"><label>3</label><institution>Department of Biological Sciences, University of Adelaide</institution><addr-line><named-content content-type="city">Adelaide</named-content></addr-line><country>Australia</country></aff><aff id="aff4"><label>4</label><institution>Lifelong Health, South Australian Health and Medical Research Institute</institution><addr-line><named-content content-type="city">Adelaide</named-content></addr-line><country>Australia</country></aff><aff id="aff5"><label>5</label><institution>UK Dementia Research Institute at the University of Cambridge and Department of Clinical Neurosciences, University of Cambridge</institution><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff6"><label>6</label><institution>School of Biosciences, Division of Natural Sciences, University of Kent</institution><addr-line><named-content content-type="city">Kent</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff7"><label>7</label><institution>MRC Toxicology Unit, University of Cambridge</institution><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United Kingdom</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Frame</surname><given-names>Margaret C</given-names></name><role>Reviewing Editor</role><aff><institution>University of Edinburgh</institution><country>United Kingdom</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Ron</surname><given-names>David</given-names></name><role>Senior Editor</role><aff><institution>University of Cambridge</institution><country>United Kingdom</country></aff></contrib></contrib-group><author-notes><fn fn-type="present-address" id="pa1"><label>†</label><p>Biotech Research and Innovation Centre, Københavns Universitet, Københavns, Denmark</p></fn><fn fn-type="present-address" id="pa2"><label>‡</label><p>NKI, Plesmanlaan, Amsterdam, Netherlands</p></fn></author-notes><pub-date date-type="publication" publication-format="electronic"><day>13</day><month>12</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>10</volume><elocation-id>e69729</elocation-id><history><date date-type="received" iso-8601-date="2021-04-24"><day>24</day><month>04</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2021-11-26"><day>26</day><month>11</month><year>2021</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2021-05-05"><day>05</day><month>05</month><year>2021</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2021.05.05.442715"/></event></pub-history><permissions><copyright-statement>© 2021, Knight et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Knight et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-69729-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-69729-figures-v1.pdf"/><abstract><p>Increased protein synthesis supports the rapid cell proliferation associated with cancer. The <italic>Rpl24<sup>Bst</sup></italic> mutant mouse reduces the expression of the ribosomal protein RPL24 and has been used to suppress translation and limit tumorigenesis in multiple mouse models of cancer. Here, we show that <italic>Rpl24<sup>Bst</sup></italic> also suppresses tumorigenesis and proliferation in a model of colorectal cancer (CRC) with two common patient mutations, <italic>Apc</italic> and <italic>Kras</italic>. In contrast to previous reports, <italic>Rpl24<sup>Bst</sup></italic> mutation has no effect on ribosomal subunit abundance but suppresses translation elongation through phosphorylation of eEF2, reducing protein synthesis by 40% in tumour cells. Ablating eEF2 phosphorylation in <italic>Rpl24<sup>Bst</sup></italic> mutant mice by inactivating its kinase, eEF2K, completely restores the rates of elongation and protein synthesis. Furthermore, eEF2K activity is required for the <italic>Rpl24<sup>Bst</sup></italic> mutant to suppress tumorigenesis. This work demonstrates that elevation of eEF2 phosphorylation is an effective means to suppress colorectal tumorigenesis with two driver mutations. This positions translation elongation as a therapeutic target in CRC, as well as in other cancers where the <italic>Rpl24<sup>Bst</sup></italic> mutation has a tumour suppressive effect in mouse models.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>translation</kwd><kwd>protein sythesis</kwd><kwd>intestinal cancer</kwd><kwd>in vivo models</kwd><kwd>RPL24</kwd><kwd>eEF2K</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000289</institution-id><institution>Cancer Research UK</institution></institution-wrap></funding-source><award-id>A17196</award-id><principal-award-recipient><name><surname>Sansom</surname><given-names>Owen J</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000289</institution-id><institution>Cancer Research UK</institution></institution-wrap></funding-source><award-id>A24388</award-id><principal-award-recipient><name><surname>Sansom</surname><given-names>Owen J</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000289</institution-id><institution>Cancer Research UK</institution></institution-wrap></funding-source><award-id>A21139</award-id><principal-award-recipient><name><surname>Sansom</surname><given-names>Owen J</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100010663</institution-id><institution>H2020 European Research Council</institution></institution-wrap></funding-source><award-id>311301</award-id><principal-award-recipient><name><surname>Sansom</surname><given-names>Owen J</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004440</institution-id><institution>Wellcome Trust</institution></institution-wrap></funding-source><award-id>201487</award-id><principal-award-recipient><name><surname>Mallucci</surname><given-names>Giovanna R</given-names></name><name><surname>von der Haar</surname><given-names>Tobias</given-names></name><name><surname>Smales</surname><given-names>Christopher Mark</given-names></name><name><surname>Willis</surname><given-names>Anne E</given-names></name><name><surname>Sansom</surname><given-names>Owen J</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000925</institution-id><institution>National Health and Medical Research Council</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Proud</surname><given-names>Christopher</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection, and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Signalling that maintains rapid translation elongation in KRAS-mutant colorectal cancer models can be targeted by mutation of the ribosomal protein RPL24 to suppress tumour proliferation.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Tumour cells require rapid protein synthesis to acquire sufficient biomass in order to divide and, as such, protein synthesis is directly regulated by many oncogenic signalling pathways (<xref ref-type="bibr" rid="bib32">Proud, 2019</xref>; <xref ref-type="bibr" rid="bib34">Robichaud et al., 2019</xref>; <xref ref-type="bibr" rid="bib42">Smith et al., 2021</xref>). As well as exploiting protein synthesis to drive cell division, cancers use translation to selectively synthesise a proteome geared towards proliferation, survival, and immune evasion. For example, in colorectal cancer (CRC) translation of the mRNA encoding the proto-oncogene c-MYC is selectively upregulated by eIF4E and mTORC1 signalling (<xref ref-type="bibr" rid="bib23">Knight et al., 2020a</xref>). Likewise, independent reports have shown that the expression of the immune suppressive ligand PD-L1 is maintained on tumour cells by the activity of the translation factors eIF4A and eIF5B as well as phosphorylation of eIF4E and eIF2α (<xref ref-type="bibr" rid="bib45">Suresh et al., 2020</xref>; <xref ref-type="bibr" rid="bib47">Xu et al., 2019</xref>; <xref ref-type="bibr" rid="bib6">Cerezo et al., 2018</xref>).</p><p><italic>APC</italic> is the most commonly mutated gene in CRC, followed by <italic>TP53</italic> and then <italic>KRAS</italic> (<xref ref-type="bibr" rid="bib14">Guinney et al., 2015</xref>). We have previously shown that <italic>Apc</italic>-deficient mouse models of CRC are dependent on fast translation elongation, a process which can be suppressed by rapamycin leading to near complete reversal of tumorigenesis (<xref ref-type="bibr" rid="bib10">Faller et al., 2015</xref>). This approach has had clinical success, where rapamycin (sirolimus) regressed <italic>APC</italic>-deficient polyps of familial adenomatous polyposis patients in two independent clinical trials (<xref ref-type="bibr" rid="bib48">Yuksekkaya et al., 2016</xref>; <xref ref-type="bibr" rid="bib35">Roos et al., 2020</xref>). Clinical data also suggest that CRCs increase translation elongation to potentiate proliferation, exemplified by the lower expression of the inhibitory kinase eEF2K correlating with worse patient survival (<xref ref-type="bibr" rid="bib30">Ng et al., 2019</xref>). However, the regulation of translation elongation in CRC is complex, notably being influenced by specific cancer-associated mutations. We have shown that mutation of <italic>Kras</italic> drives resistance to rapamycin in <italic>Apc</italic>-deficient models both in terms of its effect on elongation and on proliferation (<xref ref-type="bibr" rid="bib23">Knight et al., 2020a</xref>). This is consistent with <italic>KRAS</italic>-mutant CRCs being resistant to rapalogues, and other therapeutics (<xref ref-type="bibr" rid="bib29">Ng et al., 2013</xref>; <xref ref-type="bibr" rid="bib43">Spindler et al., 2013</xref>; <xref ref-type="bibr" rid="bib8">DeStefanis et al., 2019</xref>) and highlights the unmet need for effective therapies against <italic>KRAS</italic>-mutant cancers. Indeed, a recently developed compound covalently targeting the <italic>Kras</italic><sup><italic>G12C</italic></sup> mutation has shown remarkable potency against this specific mutation (<xref ref-type="bibr" rid="bib16">Hong et al., 2020</xref>).</p><p>Evidence suggests that targeting translation in <italic>KRAS</italic>-mutant CRC can be effective. As well as our recent study re-sensitising <italic>Kras</italic>-mutant CRCs to rapamycin by targeting translation initiation (<xref ref-type="bibr" rid="bib23">Knight et al., 2020a</xref>), we have demonstrated that <italic>Kras</italic>-mutant models of CRC depend upon the transporter SLC7A5 to maintain protein synthesis by facilitating the influx of amino acids (<xref ref-type="bibr" rid="bib28">Najumudeen et al., 2021</xref>). These data support protein synthesis as a tractable target in CRC, with the discovery of additional factors regulating these pathways only improving the potential to target protein synthesis in the clinic (<xref ref-type="bibr" rid="bib25">Knight and Sansom, 2021</xref>).</p><p>In this study, we analyse the previously characterised <italic>Rpl24<sup>Bst</sup></italic> mutation in models of CRC with <italic>Apc</italic> deletion and <italic>Kras</italic> mutations. This spontaneously arising four nucleotide deletion in the <italic>Rpl24</italic> gene, which encodes RPL24 (a component of the 60S ribosomal subunit also called large ribosomal protein subunit eL24), disrupts splicing of its mRNA, effectively resulting in a <italic>Rpl24</italic> heterozygous animal (<xref ref-type="bibr" rid="bib31">Oliver et al., 2004</xref>). Animals present with impaired dorsal pigmentation and malformed tails, among other defects, leading to the designation of a belly spot and tail (Bst) phenotype and the <italic>Rpl24<sup>Bst</sup></italic> designation. This tool has been used to suppress overall protein synthesis in genetically engineered mouse models of c-MYC-driven B-cell lymphoma, <italic>Pten</italic>-deficient T-cell acute lymphoblastic leukaemia, T-cell-specific <italic>Akt2</italic> activation and a carcinogen-driven model of bladder cancer (<xref ref-type="bibr" rid="bib3">Barna et al., 2008</xref>; <xref ref-type="bibr" rid="bib40">Signer et al., 2014</xref>; <xref ref-type="bibr" rid="bib17">Hsieh et al., 2010</xref>; <xref ref-type="bibr" rid="bib19">Jana et al., 2021</xref>). In these studies, tumorigenesis increased total protein synthesis, which was rescued by the <italic>Rpl24<sup>Bst</sup></italic> mutation. Suppression of protein synthesis was sufficient to slow tumorigenesis, with some <italic>Rpl24<sup>Bst/+</sup></italic> mice surviving over three times longer than the median survival of tumour model mice wild-type for <italic>Rpl24</italic>. However, the means by which the <italic>Rpl24<sup>Bst</sup></italic> mutation suppresses protein synthesis was not addressed in these studies, instead deferring to the original observation that there is likely a defect in ribosome production (<xref ref-type="bibr" rid="bib31">Oliver et al., 2004</xref>).</p><p>Here, we show that decreased expression of RPL24 suppresses proliferation and extends survival in an <italic>Apc</italic>-deficient <italic>Kras</italic>-mutant pre-clinical mouse model of CRC. Importantly, we find that reduced RPL24 does not alter the available pool of ribosomal subunits, as previously suggested, but instead alters signalling that regulates a translation factor. Specifically, we observe increased phosphorylation of eEF2, an event that inhibits translation elongation. We directly measure translation elongation to show that the <italic>Rpl24<sup>Bst</sup></italic> mutation suppresses protein synthesis at the elongation step, consistent with increased phosphorylation of eEF2. Reducing P-eEF2 by inactivating its inhibitory kinase, eEF2K, completely restores translation elongation and protein synthesis rates as well as reversing the beneficial effect of <italic>Rpl24<sup>Bst</sup></italic> mutation in our tumour models. Interestingly, we find that the <italic>Rpl24<sup>Bst</sup></italic> mutation has no effect in <italic>Kras</italic> wild-type models. We attribute this to a specific requirement for physiological RPL24 in <italic>Kras</italic>-mutant cells, which may provide additional mechanisms to target these cells clinically.</p><p>Finally, we provide evidence from transcriptomic and proteomic analyses of patient tissue that supports the signalling pathways uncovered in our pre-clinical models being altered in the human disease. Altogether this work demonstrates that the <italic>Rpl24<sup>Bst</sup></italic> mutation is tumour suppressive in <italic>Kras</italic>-mutant CRC and elucidates an unexpected mode of action underlying its impact on protein synthesis. This has implications for targeting translation elongation in cancer and provides mechanistic insight to supplement the previously published efficacy of the <italic>Rpl24<sup>Bst</sup></italic> mouse in models of cancer and other diseases.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title><italic>Rpl24</italic><sup><italic>Bst</italic></sup> mutation does not alter intestinal homeostasis but suppresses the rate of translation</title><p>Prior to addressing the role of RPL24 in intestinal tumorigenesis we first analysed whether the <italic>Rpl24<sup>Bst</sup></italic> mutation had any effect on normal intestinal homeostasis (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). We observed a reduction in RPL24 expression (<xref ref-type="fig" rid="fig1">Figure 1B</xref>), but no differences in intestinal architecture, proliferation shown by BrdU incorporation (<xref ref-type="fig" rid="fig1">Figure 1B</xref>) or abundance of stem cells (<italic>Olfm4</italic>), Paneth cells (lysozyme), or goblet cells (AB/PAS) (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>). Similarly, homeostasis in the colons of <italic>Rpl24<sup>Bst</sup></italic> mutant mice was unaffected, exemplified by no change in proliferation scored by BrdU incorporation (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C</xref>). In accordance with these in vivo observations, ex vivo organoids made from the small intestines of <italic>Rpl24<sup>Bst/+</sup></italic> mice established in culture and grew comparably to wild-type controls (<xref ref-type="fig" rid="fig1">Figure 1C</xref> and <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A</xref>). Surprisingly, we measured a &gt;40% reduction in total protein synthesis, by <sup>35</sup>S-methionine labelling, in <italic>Rpl24<sup>Bst/+</sup></italic> organoids compared to wild-type counterparts (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). Therefore, despite no change in homeostasis, <italic>Rpl24<sup>Bst</sup></italic> mutation had a dramatic effect on protein synthesis. This indicates a resistance to reduced protein synthesis in the wild-type intestine, which appears to function normally despite a dramatic reduction in protein output.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title><italic>Rpl24<sup>Bst</sup></italic> mutation slows translation elongation but does not affect homeostasis in the intestinal epithelium.</title><p>(<bold>A</bold>) Schematic representation of experimental procedure. Intestines from wild-type or <italic>Rpl24<sup>Bst/+</sup></italic> mice were analysed by histology or processed to make intestinal organoids. (<bold>B</bold>) Staining for H&amp;E, BrdU, RPL24, and P-eEF2 T56 in sections from the small intestines of wild-type and <italic>Rpl24<sup>Bst/+</sup></italic> mice. Red brackets in P-eEF2 staining indicate crypts and villi, corresponding to quantification to the right. Bars represent 50 µm. Graphs on the right show scoring for BrdU-positive cells, and <italic>H</italic>-score calculated for RPL24 and P-eEF2 T-56, plotted ± standard error of the mean (SEM). Significance was determined by one-tailed Mann–Whitney <italic>U</italic> test. (<bold>C</bold>) Micrographs of small intestinal organoids generated from wild-type or <italic>Rpl24<sup>Bst/+</sup></italic> mice. (<bold>D</bold>) Protein synthesis rate quantified by <sup>35</sup>S-methionine incorporation in wild-type or <italic>Rpl24<sup>Bst/+</sup></italic> organoids (<italic>n</italic> = 3), expressed relative to the wild-type protein synthesis rate (=1). Data are from three biologically independent organoid lines for each genotype represented ± SEM with significance determine by Mann–Whitney <italic>U</italic> test. (<bold>E</bold>) Representative polysome profiling from wild-type or <italic>Rpl24<sup>Bst/+</sup></italic> organoids. Average polysome:subpolysome ratios from three independent organoid lines per genotype are shown above each profile ± SEM. (<bold>F</bold>) Western blotting from protein lysates generated from three biologically independent organoid lines for each genotype. Values for RPL24 expression relative to β-actin and P-eEF2 T56 relative to eEF2 are shown under each lane. The average of the wild-type lanes in both cases has been set to 1. There is a 47% reduction in RPL24 and a 66% increase in P-eEF2 T56 in the <italic>Rpl24<sup>Bst/+</sup></italic> organoids. (<bold>G</bold>) Schematic of the potential role of RPL24 in regulating protein synthesis via eEF2. All scale bars are 50 μm.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Top: data from <xref ref-type="fig" rid="fig4">Figure 4F</xref>.</title><p>Bottom: original western blotting images with areas for each antibody annotated and boxed in red.</p></caption><media mime-subtype="pdf" mimetype="application" xlink:href="elife-69729-fig1-data1-v1.pdf"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-69729-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title><italic>Rpl24<sup>Bst</sup></italic> mutation does not affect intestinal homeostasis.</title><p>(<bold>A</bold>) Representative images of staining for intestinal lineages and translation associated phosphorylation sites – P-4E-BP1 T37/46, P-RPS6 S240/4, and P-eIF2α S51 of intestinal sections from wild-type and <italic>Rpl24<sup>Bst/+</sup></italic> mice. <italic>Olfm4</italic> defines stem cells, lysozyme for Paneth cells, and AB/PAS (Alcian blue/periodic acid-Schiff) for goblet cells. Bars represent 50 µm. (<bold>B</bold>) <italic>H</italic>-Score quantification of P-RPS6 S240/4, P-4E-BP1 T37/46, and P-eIF2α S51 from the same experiment as in (<bold>A</bold>). (<bold>C</bold>) BrdU staining of the medial colon from wild-type and <italic>Rpl24<sup>Bst</sup></italic> mice, top, with scoring of BrdU-positive cells per half crypt/villus axis below. Scores are from 3 mice per genotype, each plotted as the average of at least 20 axes. All scale bars are 50 μm.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-69729-fig1-figsupp1-v1.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title><italic>Rpl24<sup>Bst</sup></italic> mutation does not alter proliferation in organoids or the 60S:40S ratio, but does suppress regeneration post irradiation.</title><p>(<bold>A</bold>) Organoids either wild-type of mutant for <italic>Rpl24<sup>Bst</sup></italic> were grown over 4 days and the change in growth plotted relative to day 1. Triplicate independent lines were used for each genotype, with the average of these plotted on the graph ± standard error of the mean (standard error of the mean, SEM). Lack of significance was determined by Mann–Whitney <italic>U</italic> test. (<bold>B</bold>) Area under the curve for 40S and 60S ribosomal subunits was determined from the traces in <xref ref-type="fig" rid="fig1">Figure 1E</xref>. Data are from three independent biological replicates ± SEM. (<bold>C</bold>) Wild-type or <italic>Rpl24<sup>Bst</sup></italic> mice were given 10 Gy of irradiation then sampled 72 hr later. The number of regenerative crypts was quantified from at least six cross sections and the average plotted relative to wild-type regeneration set as 1 (<italic>n</italic> = 4 per genotype). Micrograph insets show representative sections of intestine for wild-type (black box) and <italic>Rpl24<sup>Bst/+</sup></italic> (green box) mice. Red arrows indicate regenerating crypts. Bars represent 50 µm. Data are represented as the mean ± SEM with significance determined by Mann–Whitney <italic>U</italic> test. All scale bars are 50 μm.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-69729-fig1-figsupp2-v1.tif"/></fig></fig-group><p>We then investigated how <italic>Rpl24<sup>Bst</sup></italic> mutation suppresses translation. Performing sucrose density gradients to quantify the number of ribosomes engaged in active translation we observed an increase in ribosomes bound to mRNAs in polysomes in <italic>Rpl24<sup>Bst/+</sup></italic> organoids, particularly the heavy polysomes (<xref ref-type="fig" rid="fig1">Figure 1E</xref>). This appears to contradict the reduction in global protein synthesis observed in <xref ref-type="fig" rid="fig1">Figure 1D</xref>. However, we and others have previously observed increased polysomes in conjunction with reduced protein synthesis in model systems where translation elongation is reduced (e.g. <xref ref-type="bibr" rid="bib22">Knight et al., 2015</xref>; <xref ref-type="bibr" rid="bib10">Faller et al., 2015</xref>). In these instances, slowed translation elongation increased the abundance of polysomes via changes in the phosphorylation of the elongation factor eEF2. We therefore assayed the regulatory phosphorylation of eEF2 (threonine 56/T56) in wild-type and <italic>Rpl24<sup>Bst</sup></italic> mutant samples. This phosphorylation event excludes eEF2 from the ribosome thereby impairing the translocation step of translation elongation, reducing protein synthesis (<xref ref-type="bibr" rid="bib37">Ryazanov and Davydova, 1989</xref>; <xref ref-type="bibr" rid="bib5">Carlberg et al., 1990</xref>).</p><p>In small intestinal tissue assayed by immunohistochemistry (IHC) we observed an increase in P-eEF2 T56, specifically in the proliferating crypt and transit amplifying zone of <italic>Rpl24<sup>Bst/+</sup></italic> mouse intestines (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). Likewise, we observed a 66% increase in P-eEF2 T56 in lysates generated from <italic>Rpl24<sup>Bst/+</sup></italic> organoids compared to wild-type organoids (<xref ref-type="fig" rid="fig1">Figure 1F</xref>). These organoids also showed a 47% reduction in RPL24 expression by western blot (<xref ref-type="fig" rid="fig1">Figure 1F</xref>). Thus, in these two proliferative settings (intestinal crypts in situ and ex vivo organoids) <italic>Rpl24<sup>Bst</sup></italic> mutation increases the phosphorylation of eEF2, which is known to suppress translation. Surprisingly, we observed that in the differentiated villus, <italic>Rpl24<sup>Bst</sup></italic> mutation suppressed P-eEF2 T56 (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). The reasons for this are unclear but may relate to different cell functions in the two compartments. This effect on P-eEF2 T56 is specific, as we observed no effect on the phosphorylation of other translation related proteins, 4E-BP1 or RPS6 (at S240/S244), readouts for modulation of signalling downstream of mTORC1 (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A, B</xref>). Similarly, we saw no change in the phosphorylation of the translation stress marker eIF2α in <italic>Rpl24<sup>Bst</sup></italic> mutant mice (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A, B</xref>).</p><p>Altogether, this analysis of wild-type tissue indicates that physiological RPL24 expression is not required for proliferation or function, but reduction of RPL24 expression reduces the rate of translation. Interestingly, this involves regulation of translation elongation and correlates with increased P-eEF2 (<xref ref-type="fig" rid="fig1">Figure 1G</xref>). Previously the <italic>Rpl24<sup>Bst</sup></italic> mutation had been suggested to suppress ribosome biogenesis, resulting in uneven 40S and 60S ratios. However, we observed no alteration in the relative levels of the 40S and 60S subunits in sucrose density gradients (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2B</xref>), consistent with previous reports that RPL24 deletion has negligible effect on ribosome biogenesis (<xref ref-type="bibr" rid="bib2">Barkić et al., 2009</xref>).</p><p>The wild-type mouse intestine regenerates following γ-irradiation, dependent on Wnt and mitogen-activated protein kinase (MAPK) signalling pathways. These pathways are often deregulated in colorectal tumours, such that this intestinal regeneration acts as a surrogate for oncogenic potential, with reduced regenerative capacity indicative of reduced tumorigenic proliferation (<xref ref-type="bibr" rid="bib10">Faller et al., 2015</xref>). We observe that mutation of <italic>Rpl24</italic> restricts regeneration of the small intestine (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2C</xref>). Thus, RPL24 expression enables regeneration, which may correlate with effects in tumorigenesis.</p></sec><sec id="s2-2"><title>RPL24 is required for proliferation in <italic>Apc</italic>-deficient <italic>Kras</italic>-mutant intestinal tumours</title><p>Next, we analysed the effect of the <italic>Rpl24<sup>Bst</sup></italic> mutation on a model of CRC driven by tamoxifen inducible <italic>Villin<sup>CreER</sup></italic>-mediated deletion of <italic>Apc</italic> and activation of KRAS with a G12D mutation. This model can be used with homozygous deletion of <italic>Apc</italic> (<italic>Apc<sup>fl/fl</sup></italic>) where intestinal hyperproliferation generates a short-term (3–4 days) model or with heterozygous deletion of <italic>Apc</italic> (<italic>Apc<sup>fl/+</sup></italic>) where intestinal adenomas form following spontaneous loss of the second copy of <italic>Apc</italic>. The recombination of a lox-STOP-lox allele at the endogenous <italic>Kras</italic> locus expresses a constitutively active G12D mutant form of the protein. Mice were generated with the <italic>Apc<sup>fl/fl</sup></italic> and <italic>Kras<sup>G12D</sup></italic> alleles with and without the <italic>Rpl24<sup>Bst</sup></italic> mutation (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Hyperproliferation in the <italic>Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup> Rpl24<sup>Bst/+</sup></italic> mutant mice was significantly suppressed compared to <italic>Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup></italic> control mice (<xref ref-type="fig" rid="fig2">Figure 2B, C</xref>). Reduced RPL24 expression was confirmed by IHC (<xref ref-type="fig" rid="fig2">Figure 2C</xref>) and coincided with increased P-eEF2 throughout the proliferative crypt area of the <italic>Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup> Rpl24<sup>Bst/+</sup></italic> intestine (<xref ref-type="fig" rid="fig2">Figure 2C</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). Hyperproliferation in the colon mirrored that of the small intestine, with reduced proliferation in mice mutant for <italic>Rpl24</italic> compared to those expressing wild-type levels of RPL24 (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). In parallel, organoids were derived from the small intestines of the same genotypes (<italic>Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup></italic> and <italic>Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup> Rpl24<sup>Bst/+</sup></italic>) and their growth compared. <italic>Rpl24<sup>Bst</sup></italic> mutation resulted in significantly less proliferation ex vivo (<xref ref-type="fig" rid="fig2">Figure 2D</xref>), consistent with the in vivo experiment shown in <xref ref-type="fig" rid="fig2">Figure 2B</xref>.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title><italic>Rpl24<sup>Bst</sup></italic> mutation suppresses proliferation and extends survival in an <italic>Apc</italic>-deficient <italic>Kras</italic>-mutant mouse model of colorectal cancer (CRC).</title><p>(<bold>A</bold>) Schematic representation of experimental protocols. <italic>Villin<sup>CreER</sup> Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup></italic> or <italic>Villin<sup>CreER</sup> Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup> Rpl24<sup>Bst/+</sup></italic> mice were induced by intraperitoneal injection of tamoxifen at 80 mg/kg then intestinal tissue analysed 3 days later. Tissue was taken for histological analysis or processed into intestinal organoids. (<bold>B</bold>) Quantification of BrdU incorporation in small intestinal crypt/villus axes following deletion of <italic>Apc</italic> and activation of <italic>Kras</italic>, with (<italic>n</italic> = 4) or without (<italic>n</italic> = 3) <italic>Rpl24<sup>Bst</sup></italic> mutation. Data are represented as the mean number of BrdU-positive cells per half crypt/villus from &gt;20 axes per mouse ± standard error of the mean (SEM). Significance was determined by Mann–Whitney <italic>U</italic> test. (<bold>C</bold>) Representative images of intestines from the same experiment as in (<bold>B</bold>), stained for H&amp;E, BrdU, P-eEF2 T56, and RPL24. The red bar on the H&amp;E images indicates the extent of the proliferative zone. Bars represent 50 µm. (<bold>D</bold>) <italic>Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup></italic> organoids with or without <italic>Rpl24<sup>Bst</sup></italic> mutation were grown for 4 days and growth relative to day 1 determined by Cell-Titer Blue assay. Data show the mean ± SEM of <italic>n</italic> = 3 independent organoid lines. Significance was determined by one-tailed Mann–Whitney <italic>U</italic> test. (<bold>E</bold>) Top: schematic of experimental protocol. <italic>Villin<sup>CreER</sup> Apc<sup>fl/+</sup> Kras<sup>G12D/+</sup></italic> or <italic>Villin<sup>CreER</sup> Apc<sup>fl/+</sup> Kras<sup>G12D/+</sup> Rpl24<sup>Bst/+</sup></italic> mice induced with 80 mg/kg tamoxifen then monitored until clinical endpoint. Survival plot for these genotypes for the days post-induction that they reached endpoint. The median survival and <italic>n</italic> number for each cohort are shown and significance determined by Mantel–Cox test. Censored subjects were removed from the study due to non-intestinal phenotypes. All scale bars are 50 μm.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-69729-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title><italic>Rpl24Bst</italic> mutation leads to increased eEF2 phosphorylation.</title><p>(<bold>A</bold>) Top: Schematic representation of experimental approach. <italic>Villin<sup>CreER</sup> Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup></italic>, <italic>Villin<sup>CreER</sup> Apc<sup>fl/fl</sup> Kras</italic><sup>G12D/+</sup> <italic>Rpl24<sup>Bst/+</sup></italic>, or <italic>Villin<sup>CreER</sup> Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup> Rpl24<sup>Bst/+</sup> Eef2k<sup>D273A/D273A</sup></italic> mice were induced by intraperitoneal injection of tamoxifen at 80 mg/kg then intestinal tissue analysed 3 days later. Bottom: Staining for P‐4E‐BP1 T37/46, P‐RPS6 S240/4, and P‐eIF2α S51 from the genotypes above. <italic>Villin<sup>CreER</sup> Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup> Rpl24<sup>Bst/+</sup> Eef2k<sup>D273A/D273A</sup></italic> intestines were not stained for P‐eIF2α S51. Right: H‐score quantification for P‐eEF2 T56 (matched to images shown in <xref ref-type="fig" rid="fig2">Figures 2C</xref> and <xref ref-type="fig" rid="fig5">5C</xref>), P‐4E‐BP1 T37/46, P‐RPS6 S240/4, and P‐eIF2α S51 . Small intestines from at least 3three animals from each genotype (<italic>Apc<sup>fl/+</sup> Kras<sup>G12D/+</sup></italic>, <italic>Apc<sup>fl/+</sup> Kras<sup>G12D/+</sup> Rpl24<sup>Bst/+</sup></italic>, and <italic>Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup> Rpl24<sup>Bst/+</sup> Eef2k<sup>D273A/D273A</sup></italic>) were stained and the intensity quantified from the proliferative crypt region. Data are plotted ± standard error of the mean (standard error of the mean, SEM). Significance was determined by one‐way analysis of variance (ANOVA) analysis with Tukey’s multiple comparison. (<bold>B</bold>) Left: Representative micrograph images of each genotype stained for BrdU in the medial colons of <italic>Villin<sup>CreER</sup> Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup></italic> and <italic>Villin<sup>CreER</sup> Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup> Rpl24<sup>Bst/+</sup></italic> mice. Right: Scores for BrdU positivity from 4 mice per genotype, each plotted as the average of at least 20 half crypt/villi. Significance was determined by Mann– Whitney U test.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-69729-fig2-figsupp1-v1.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title><italic>Rpl24<sup>Bst</sup></italic> mutation suppresses proliferation in cells from colorectal cancer models.</title><p>(<bold>A</bold>) Top: schematic showing the generation of colonic adenoma cultures, where <italic>Villin<sup>CreER</sup> Apc<sup>fl/+</sup> Kras<sup>G12D/+</sup></italic> and <italic>Villin<sup>CreER</sup> Apc<sup>fl/+</sup> Kras<sup>G12D/+</sup> Rpl24<sup>Bst/+</sup></italic> mice were induced and aged until colonic tumours were present. Individual adenomas were then excised and cells isolated. Bottom: Growth of these cultures over 4 days, plotted relative to day 1. Biologically independent triplicate organoid lines were used, with the averages plotted ± SEM. Significance was tested by Mann– Whitney U test. (<bold>B</bold>) Tumour number (left) and total tumour volume (right) for indicated tumour models. Each point represents and individual mouse. From left to right n = 16, 11, 21, 13, 19, and 8 mice.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-69729-fig2-figsupp2-v1.tif"/></fig></fig-group><p>In the tumour model, where a single copy of <italic>Apc</italic> is deleted, <italic>Apc<sup>fl/+</sup> Kras<sup>G12D/+</sup> Rpl24<sup>Bst/+</sup></italic> mice lived on average 32 days longer than <italic>Apc<sup>fl/+</sup> Kras<sup>G12D/+</sup></italic> controls, an extension of survival of 45% (<xref ref-type="fig" rid="fig2">Figure 2E</xref>). Furthermore, <italic>Apc<sup>fl/+</sup> Kras<sup>G12D/+</sup> Rpl24<sup>Bst/+</sup></italic> organoids derived from the adenomas in this tumour model grew more slowly than controls (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>). There was no significant difference in the number or volume of tumours at experimental endpoint (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>), indicating that adenomas can form but take longer to reach a clinically significant burden. Therefore, RPL24 enables proliferation in <italic>Apc</italic>-deficient, KRAS-activated cells within the intestinal epithelium of the mouse.</p></sec><sec id="s2-3"><title>RPL24 maintains translation elongation in <italic>Apc</italic>-deficient <italic>Kras</italic>-mutant intestinal tumour models</title><p>The suppression of tumorigenesis in the <italic>Apc</italic>-deficient <italic>Kras</italic>-mutant model correlated with increased phosphorylation of eEF2 (<xref ref-type="fig" rid="fig2">Figure 2C</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). Increased P-eEF2 was not accompanied by increased P-eIF2α, which controls translation initiation in response to various stress signals (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). This indicates that stress signalling to eIF2α was not influenced by the <italic>Rpl24<sup>Bst</sup></italic> mutation, highlighting the specificity in the RPL24-dependent regulation of eEF2. To investigate this further we used three methods to measure the rate of translation: polysome profiling, <sup>35</sup>S-methionine labelling, and harringtonine run-off assays (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). Polysome profiling from extracted crypts from <italic>Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup></italic> and <italic>Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup> Rpl24<sup>Bst/+</sup></italic> mice showed an increase in polysomes with the <italic>Rpl24</italic> mutation (<xref ref-type="fig" rid="fig3">Figure 3B</xref>), and notably a significant increase in the quantity of heavy polysomes (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). Intestinal organoids of the same genotype showed a 35% reduction in <sup>35</sup>S-methionine incorporation (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). These same organoids had a greater than 40% decrease in elongation rate measured by harringtonine run-off (<xref ref-type="fig" rid="fig3">Figure 3E</xref> and <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>). Together these data provide compelling evidence that normal RPL24 expression is required to maintain translation elongation in this CRC model. Polysome profiles and protein synthesis rate measurements from <italic>Apc<sup>fl/+</sup> Kras<sup>G12D/+</sup> Rpl24<sup>Bst/+</sup></italic> adenoma cultures also showed more polysomes and lower protein synthesis compared to control adenoma cultures (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B, C</xref>). The reduced protein synthesis rate does not correlate with differences in free ribosomal subunit availability as the ratio of 40S to 60S subunits is unchanged by the <italic>Rpl24</italic> mutation in <italic>Apc</italic>-deficient <italic>Kras</italic>-mutant cells (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1D</xref>). To investigate this further we assayed selected ribosomal protein abundances in <italic>Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup></italic> and <italic>Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup> Rpl24<sup>Bst/+</sup></italic> organoids by western blot. RPL10 expression was increased by the <italic>Rpl24</italic> mutation, RPL22 was decreased, while RPS6 levels were unchanged (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1E</xref>). While the significance of these individual changes is unknown, the data show that there is not a global suppression of ribosomal protein expression in <italic>Rpl24</italic> mutant cells, consistent with no change in free ribosomal subunit levels.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title><italic>Rpl24<sup>Bst</sup></italic> mutation slows translation elongation in <italic>Apc</italic>-deficient <italic>Kras</italic>-mutant mouse models of colorectal cancer (CRC).</title><p>(<bold>A</bold>) Schematic representation of experimental approach. <italic>Villin<sup>CreER</sup> Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup></italic> or <italic>Villin<sup>CreER</sup> Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup> Rpl24<sup>Bst/+</sup></italic> mice were induced by intraperitoneal injection of tamoxifen at 80 mg/kg then intestinal tissue analysed 3 days later. Intestines were enriched for crypt epithelium for sucrose density analysis or processed into intestinal organoids. (<bold>B</bold>) Representative sucrose density polysome profiles generated from <italic>Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup></italic> intestinal extracts with or without the <italic>Rpl24<sup>Bst</sup></italic> mutation. Subpolysomal components (40S, 60S, and 80S) and polysomes are labelled, with the polysomes also split pictorially into light and heavy. (<bold>C</bold>) Quantification of the heavy:light polysome ratio from the experiment in (<bold>B</bold>). Data show the mean of analysis from three mice ± standard error of the mean (standard error of the mean, SEM) with significance determined by one-tailed Mann–Whitney <italic>U</italic> test. (<bold>D</bold>) Relative protein synthesis rate quantified by <sup>35</sup>S-methionine incorporation in <italic>Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup></italic> three biologically independent organoid lines either wild-type or mutant for <italic>Rpl24<sup>Bst</sup></italic>. Data are represented ± SEM with significance determine by Mann–Whitney <italic>U</italic> test. (<bold>E</bold>) Ribosome run-off rate determined in <italic>Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup></italic> small intestinal organoid lines either wild-type or mutant for <italic>Rpl24<sup>Bst</sup></italic> (<italic>n</italic> = 3 per genotype). Data are represented as the mean of three biological replicates ± SEM with significance determine by Mann–Whitney <italic>U</italic> test. Raw data are available in <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>. (<bold>F</bold>) Schematics of the regulation of protein synthesis and tumour proliferation downstream of RPL24. Smaller RPL24 in bottom scheme represents reduced RPL24 expression. ‘P’ represents phosphorylation of eEF2.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-69729-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>The effect of <italic>Rpl24<sup>Bst</sup></italic> mutation on translation and ribosome composition.</title><p>(<bold>A</bold>) Representative polysome profiles from <italic>Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup></italic> or <italic>Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup> Rpl24<sup>Bst/+</sup></italic> small intestinal organoid cultures, pre-treated with harringtonine for 5 min/300 s (H300) or untreated (H0). These traces were analysed for the run-off rates shown in <xref ref-type="fig" rid="fig3">Figure 3E</xref>. (<bold>B</bold>) Representative polysome profiles from <italic>Apc<sup>fl/+</sup> Kras<sup>G12D/+</sup></italic> or <italic>Apc<sup>fl/+</sup> Kras<sup>G12D/+</sup> Rpl24<sup>Bst/+</sup></italic> colonic adenoma cultures (left) and quantification of the polysome to subpolysome ratio from these (right). Two biologically independent lines were analysed per genotype and plotted ± standard error of the mean (SEM). Scheme above denotes the generation of adenoma cultures from distinct colonic tumours in aged <italic>Villin<sup>CreER</sup> Apc<sup>fl/+</sup> Kras<sup>G12D/+</sup></italic> and <italic>Villin<sup>CreER</sup> Apc<sup>fl/+</sup> Kras<sup>G12D/+</sup> Rpl24<sup>Bst/+</sup></italic> mice. (<bold>C</bold>) Relative protein synthesis rates quantified by <sup>35</sup>S-methionine incorporation in the colonic adenoma cultures described in (<bold>B</bold>) with <italic>n</italic> = 3. The average protein synthesis rates were plotted relative to <italic>Apc<sup>fl/+</sup> Kras<sup>G12D/+</sup></italic> controls (=1) for three organoid lines per genotype ± SEM. Significance was determined by Mann–Whitney <italic>U</italic> test. (<bold>D</bold>) 60S to 40S ratio from sucrose density gradients from lysates generated from the indicated genotypes. Data show the mean ± SEM. Representative traces are shown in <xref ref-type="fig" rid="fig3">Figure 3B</xref> and <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2B</xref>. (<bold>E</bold>) Western blotting from protein lysates generated from three biologically independent organoid lines for each genotype. Mean values for RPL24, RPL10, RPL22, and RPS6 expression relative to β-actin and P-eEF2 T56 relative to eEF2 are shown next to the relevant blot ± SEM. The average of the <italic>Villin<sup>CreER</sup> Apc<sup>fl/+</sup> Kras<sup>G12D/+</sup></italic> lanes in all cases has been set to 1.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-69729-fig3-figsupp1-v1.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>Assocation of ribosomal proteins with the ribosomes in <italic>Rpl24<sup>Bst</sup></italic> mutant and wild-type organoids.</title><p>Top: protein purified from sucrose density gradients performed on <italic>Villin<sup>CreER</sup> Apc<sup>fl/+</sup> Kras<sup>G12D/+</sup></italic> and <italic>Villin<sup>CreER</sup> Apc<sup>fl/+</sup> Kras<sup>G12D/+</sup> Rpl24<sup>Bst/+</sup></italic> organoids was resolved by sodium dodecyl sulphate–polyacrylamide gel electrophoresis (SDS–PAGE) and western blot performed for ribosomal proteins and β-tubulin, as a non-ribosomal control. Fractions within the gradient are annotated as non-ribosomal (non-ribo), 40S, 60S, 80S, and polysomes. Data are representative of three independent biological replicates. These gradients were also used in the analysis shown in <xref ref-type="fig" rid="fig3">Figure 3A, E</xref>, with these being the H0 replicates from that experiment. Bottom: quantification of RPL24 and RPL10 abundances, as a percentage of total cytoplasmic protein, across gradients from <italic>Villin<sup>CreER</sup> Apc<sup>fl/+</sup> Kras<sup>G12D/+</sup></italic> and <italic>Villin<sup>CreER</sup> Apc<sup>fl/+</sup> Kras<sup>G12D/+</sup> Rpl24<sup>Bst/+</sup></italic> organoids. Circles show individual values from three replicates with bars plotting the mean of these ± standard error of the mean (standard error of the mean, SEM).</p><p><supplementary-material id="fig3s2sdata1"><label>Figure 3—figure supplement 2—source data 1.</label><caption><title>Top: data from <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref>.</title><p>Bottom: original western blotting images with areas for each antibody annotated and boxed in red.</p></caption><media mime-subtype="pdf" mimetype="application" xlink:href="elife-69729-fig3-figsupp2-data1-v1.pdf"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-69729-fig3-figsupp2-v1.tif"/></fig></fig-group><p>The reduced expression of RPL24, but maintained ribosomal subunit stoichiometry, in <italic>Rpl24<sup>Bst/+</sup></italic> mice raises the possibility of heterogeneous ribosomes (reviewed by <xref ref-type="bibr" rid="bib12">Gay et al., 2021</xref>), with some potentially lacking RPL24. To address this, we purified protein from sucrose density gradients from <italic>Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup></italic> and <italic>Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup> Rpl24<sup>Bst/+</sup></italic> organoids and analysed ribosomal protein expression within subpolysomes and polysomes (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref>). The large subunit protein RPL10 showed little change in distribution between the two genotypes, consistent with no change in free ribosomal subunit levels and a shift from light to heavy polysomes, but similar overall polysome number. Importantly, RPL24 can incorporate into 60S, 80S, and polysomes in <italic>Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup> Rpl24<sup>Bst/+</sup></italic> organoids. The distribution of RPL24 appeared altered, with less in the 60S and more in the polysomes, although this was not significant. It is difficult to interpret absolute amounts of protein in each fraction and to compare this between genotypes. However, considering that <italic>Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup> Rpl24<sup>Bst/+</sup></italic> organoids express less RPL24 (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1E</xref>) the reduction in RPL24 in 60S subunits is even more striking. Thus, our data do not rule out the possibility of ribosome heterogeneity in that some 60S subunits in <italic>Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup> Rpl24<sup>Bst/+</sup></italic> organoids may lack RPL24.</p><p>Interpreting this molecular analysis in conjunction with the effects on tumorigenesis leads to the conclusion that RPL24 expression maintains translation elongation and protein synthesis rates, which in turn maintain tumour-related proliferation (<xref ref-type="fig" rid="fig3">Figure 3F</xref>). Suppressing RPL24 expression increases P-eEF2, an effect also seen in lysates from <italic>Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup> Rpl24<sup>Bst/+</sup></italic> organoids (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1E</xref>), which decreases the rate of elongation and overall protein synthesis and correlates with suppressed tumorigenesis and proliferation in vivo.</p></sec><sec id="s2-4"><title><italic>Rpl24</italic> mutation has no effect in CRC models expressing wild-type <italic>Kras</italic></title><p>In parallel to analysing the effect of <italic>Rpl24</italic> mutation in <italic>Apc</italic>-deficient <italic>Kras</italic>-mutant intestinal tumours, we also assessed its role in <italic>Apc</italic>-deficient models wild-type for <italic>Kras</italic>. We have previously shown that these are dependent on signalling from mTORC1 to maintain low levels of P-eEF2, and that rapamycin induces P-eEF2 to great therapeutic benefit (<xref ref-type="bibr" rid="bib10">Faller et al., 2015</xref>). We observed that the hyperproliferation in the small intestine or colon of <italic>Apc<sup>fl/fl</sup></italic> mice was not reduced by the <italic>Rpl24<sup>Bst</sup></italic> mutation (<xref ref-type="fig" rid="fig4">Figure 4A, B</xref> and <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>). Furthermore, in both germline <italic>Apc<sup>Min/+</sup></italic> and inducible <italic>Apc<sup>fl/+</sup></italic> models of <italic>Apc</italic> deficiency we see no benefit of the <italic>Rpl24<sup>Bst</sup></italic> mutation, with no difference in survival or tumour development (<xref ref-type="fig" rid="fig4">Figure 4C</xref> and <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref>). In agreement, <italic>Apc<sup>fl/fl</sup></italic> organoids with the <italic>Rpl24<sup>Bst</sup></italic> mutation grew at an identical rate to those wild-type for <italic>Rpl24</italic> in culture (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). Together these data demonstrate that reduced RPL24 expression does not limit tumorigenesis in <italic>Apc</italic>-deficient CRC models with wild-type <italic>Kras</italic>.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title><italic>Rpl24<sup>Bst</sup></italic> mutation does not suppress proteins synthesis or proliferation in <italic>Apc</italic>-deficient <italic>Kras</italic> wild-type mouse models of colorectal cancer (CRC).</title><p>(<bold>A</bold>) Schematic representation of experimental approach. <italic>Villin<sup>CreER</sup> Apc<sup>fl/fl</sup></italic> or <italic>Villin<sup>CreER</sup> Apc<sup>fl/fl</sup> Rpl24<sup>Bst/+</sup></italic> mice were induced by two intraperitoneal injection of tamoxifen at 80 mg/kg on days 0 and 1 then intestinal tissue analysed on day 4. Intestines were analysed histologically or intestinal organoids generated. (<bold>B</bold>) Top: representative micrographs showing proliferation as BrdU positivity and extent of proliferation as a red bar in H&amp;E image. RPL24 and P-eEF2 T56, staining is also shown for each genotype. Bars represent 50 µm. Below: BrdU scoring from <italic>Apc<sup>fl/fl</sup></italic> or <italic>Apc<sup>fl/fl</sup> Rpl24<sup>Bst/+</sup></italic> mouse intestines and <italic>H</italic>-scores for RPL24 and P-eEF2 T56 protein levels. For BrdU scoring BrdU was administered 2 hr before sampling and at least 20 half crypt/villus axes were scored per animal and the mean plotted ± standard error of the mean (standard error of the mean, SEM). (<bold>C</bold>) <italic>Apc<sup>Min/+</sup></italic> tumour model survival curve, for mice with and without <italic>Rpl24<sup>Bst</sup></italic> mutation. Lack of a significant difference was determined by Mantel–Cox test. (<bold>D</bold>) Relative growth of <italic>Apc<sup>fl/fl</sup></italic> and <italic>Apc<sup>fl/fl</sup> Rpl24<sup>Bst/+</sup></italic> small intestinal organoids over 3 days, measure by Cell-Titer Blue assay. The average change in proliferation is plotted from three independent biological replicates per genotype. (<bold>E</bold>) Relative protein synthesis rates quantified from <sup>35</sup>S-methionine incorporation into <italic>Apc<sup>fl/fl</sup></italic>, <italic>Apc<sup>fl/fl</sup></italic> treated with 250 nM rapamycin for 24 hr and <italic>Apc<sup>fl/fl</sup> Rpl24<sup>Bst/+</sup></italic> small intestinal organoids. Significant changes were calculated by one-way analysis of variance (ANOVA) with Tukey’s multiple comparison. <italic>N</italic> = 3 per genotype with the mean protein synthesis rate for each genotype plotted ± SEM. (<bold>F</bold>) Relative expression of ribosomal protein mRNAs in <italic>Villin<sup>CreER</sup> Apc<sup>fl/fl</sup></italic> and <italic>Villin<sup>CreER</sup> Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup></italic> whole intestine samples, where wild-type tissue has been normalised to 1. The fold increase in expression from <italic>Apc<sup>fl/fl</sup></italic> to <italic>Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup></italic> samples for <italic>Rpl24</italic> and the average of all other RP mRNAs are shown. Statistical analysis was by one sample <italic>t</italic>-test of the other RP mRNA fold changes using the fold change for <italic>Rpl24</italic> mRNA as the hypothetical mean. All scale bars are 50 μm.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Data relate to <xref ref-type="fig" rid="fig4">Figure 4F</xref> and <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2D</xref>.</title><p>Raw values tab shows the tabulated RNA sequencing reads for ribosomal proteins from triplicate wild-type (WT), <italic>Villin<sup>CreER</sup> Apc<sup>fl/fl</sup></italic> (Apc) and <italic>Villin<sup>CreER</sup> Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup></italic> (Apc Kras) from whole intestine samples. Averages for the replicates are shown and fold change compared to WT expression. Average values tab shows all fold changes and the average fold change across all ribosomal proteins except <italic>Rpl24</italic>, and the fold change for <italic>Rpl24</italic> for comparison.</p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-69729-fig4-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-69729-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title><italic>Rpl24<sup>Bst</sup></italic> mutation has no benefit in a model of colorectal cancer (CRC) with wild-type <italic>Kras</italic>.</title><p>(<bold>A</bold>) Left: staining for BrdU in the medial colons of <italic>Villin<sup>CreER</sup> Apc<sup>fl/fl</sup></italic> and <italic>Villin<sup>CreER</sup> Apc<sup>fl/fl</sup> Rpl24<sup>Bst/+</sup></italic> mice. Bottom: scores are from 3 and 5 mice per genotype, each plotted as the average of at least 20 half crypt/villi. Lack of significance was determined by Mann–Whitney <italic>U</italic> test. (<bold>B</bold>) Left: schematic of experiment, <italic>Villin<sup>CreER</sup> Apc<sup>fl/+</sup></italic> mice with or without <italic>Rpl24<sup>Bst</sup></italic> mutation were induced then aged until showing signs of intestinal tumours. Right: survival curve from the <italic>Villin<sup>CreER</sup> Apc<sup>fl/+</sup></italic> tumour model, with and without <italic>Rpl24<sup>Bst</sup></italic> mutation. Censored subjects were sampled for health reasons not relating to the intestine. Lack of a significant difference was determined by Mantel–Cox test. All scale bars are 50 μm.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-69729-fig4-figsupp1-v1.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title><italic>Rpl24<sup>Bst</sup></italic> mutation has no effect on polysomes or some signaling pathways.</title><p>(<bold>A</bold>) Schematic representation of experimental approach. <italic>Villin<sup>CreER</sup> Apc<sup>fl/fl</sup></italic> or <italic>Villin<sup>CreER</sup> Apc<sup>fl/fl</sup> Rpl24<sup>Bst/+</sup></italic> mice were induced by two intraperitoneal injection of tamoxifen at 80 mg/kg on days 0 and 1 then intestinal tissue analysed on day 4. Intestines analysed histologically or by epithelial extraction for sucrose density gradient analysis. (<bold>B</bold>) Left: representative polysome profiles generated from <italic>Apc<sup>fl/fl</sup></italic> intestinal extracts with or without the <italic>Rpl24<sup>Bst</sup></italic> mutation. Subpolysomal components and polysomes are labelled. Right: quantification of the polysome:subpolysome ratio across three biologically independent replicates for each genotype. Data show the mean ± standard error of the mean (SEM). (<bold>C</bold>) Staining of small intestinal tissue for P-4E-BP1 T37/46, P-RPS6 S240/4, and P-eIF2α S51 from <italic>Villin<sup>CreER</sup> Apc<sup>fl/fl</sup></italic> or <italic>Villin<sup>CreER</sup> Apc<sup>fl/fl</sup> Rpl24<sup>Bst/+</sup></italic> mice alongside <italic>H</italic>-score quantification from the proliferative zones of the intestines of at least 3 mice per genotype. (<bold>D</bold>) Relative ribosomal protein mRNA abundances from RNA sequencing of wild-type, <italic>Villin<sup>CreER</sup> Apc<sup>fl/fl</sup></italic> and <italic>Villin<sup>CreER</sup> Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup></italic> whole small intestinal tissue. Three independent biological samples were analysed per genotype with the averages used in this analysis. RNA sequencing reads for <italic>Villin<sup>CreER</sup> Apc<sup>fl/fl</sup></italic> and <italic>Villin<sup>CreER</sup> Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup></italic> tissue was normalised to wild-type tissue set to 1. Values are shown horizontally scaled as fold changes to the wild-type tissue for each genotype. All scale bars are 50 μm.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-69729-fig4-figsupp2-v1.tif"/></fig></fig-group><p>Despite no effect on proliferation, we observed an increase in P-eEF2 in <italic>Apc<sup>fl/fl</sup> Rpl24<sup>Bst/+</sup></italic> intestines compared to <italic>Apc<sup>fl/fl</sup></italic> (<xref ref-type="fig" rid="fig4">Figure 4B</xref>), showing that P-eEF2 is consistently increased in the intestinal crypts of <italic>Rpl24<sup>Bst/+</sup></italic> mice. However, we detected no change in the ratio of polysomes to subpolysomes in <italic>Apc<sup>fl/fl</sup> Rpl24<sup>Bst/+</sup></italic> intestines compared to <italic>Apc<sup>fl/fl</sup></italic> (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2A, B</xref>) and no change in protein synthesis rate between organoids of these same genotypes (<xref ref-type="fig" rid="fig4">Figure 4E</xref>). In contrast, rapamycin treatment significantly reduces protein synthesis in <italic>Apc<sup>fl/fl</sup></italic> organoids treated in parallel (<xref ref-type="fig" rid="fig4">Figure 4E</xref>). From these data, we conclude that the change in P-eEF2 does not limit the rate of protein synthesis which allows efficient tumorigenesis in these <italic>Kras</italic> wild-type models of CRC. There was no alteration in the phosphorylation status of 4E-BP1, RPS6, or eIF2α in the <italic>Rpl24<sup>Bst</sup></italic> mutants in the <italic>Apc<sup>fl/fl</sup></italic> model (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2C</xref>), indicating that translation promoting mTORC1 signalling remains high while translation stress signalling to eIF2α is unchanged.</p><p>We hypothesised that the reason for the KRAS specificity seen with the <italic>Rpl24<sup>Bst</sup></italic> mutation may relate to expression levels between the different genotypes analysed. Using unbiased RNA sequencing data from wild-type, <italic>Apc<sup>fl/fl</sup></italic> and <italic>Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup></italic> small intestinal tissue we observed a consistent increase in ribosomal protein expression following <italic>Apc</italic> deletion, then again following KRAS activation (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2D</xref>). This is consistent with previous reports (<xref ref-type="bibr" rid="bib41">Smit et al., 2020</xref>), and a requirement to increase protein synthesis as a direct consequence of KRAS activation. Indeed, the mRNAs for all ribosomal proteins with sufficient reads were increased on average nearly 1.5-fold by KRAS activation in the small intestine (<xref ref-type="fig" rid="fig4">Figure 4F</xref>). In contrast, the <italic>Rpl24</italic> mRNA was only increased by 1.14-fold following Kras mutation, despite a nearly twofold increase following deletion of <italic>Apc</italic> (<xref ref-type="fig" rid="fig4">Figure 4F</xref>). This manifests as a significant difference in the RNA expression of <italic>Rpl24</italic> compared to the other ribosomal proteins. Therefore, RPL24 expression may be sufficient in <italic>Rpl24<sup>Bst</sup></italic> mice in <italic>Apc</italic>-deleted models, but then becomes limiting following <italic>Kras</italic> mutation due to the limited upregulation of <italic>Rpl24</italic> expression accompanying KRAS activation.</p></sec><sec id="s2-5"><title>Genetic inactivation of eEF2K completely reverses the anti-proliferative benefit of <italic>Rpl24</italic> mutation</title><p>Thus far we have demonstrated a correlation between the increase in P-eEF2 and the slowing of translation elongation following <italic>Rpl24<sup>Bst</sup></italic> mutation. To test whether the slowing of elongation caused by <italic>Rpl24<sup>Bst</sup></italic> mutation was dependent on P-eEF2, we used a whole-body point mutant of eEF2K, the kinase that phosphorylates eEF2, which almost completely inactivates its kinase activity (<xref ref-type="bibr" rid="bib13">Gildish et al., 2012</xref>). We crossed this <italic>Eef2k<sup>D273A/D273A</sup></italic> allele to the <italic>Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup> Rpl24<sup>Bst/+</sup></italic> mice to generate <italic>Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup> Rpl24<sup>Bst/+</sup> Eef2k<sup>D273A/D273A</sup></italic> mice. In the short-term hyperproliferation model, the inactivation of <italic>Eef2k</italic> completely reversed the suppression of proliferation seen in <italic>Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup> Rpl24<sup>Bst/+</sup></italic> small intestines (<xref ref-type="fig" rid="fig5">Figure 5A–C</xref>), and the medial colon (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>). The kinase inactive <italic>Eef2k</italic> allele resulted in P-eEF2 being undetectable (<xref ref-type="fig" rid="fig5">Figure 5C</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>), and we previously reported no difference in hyperproliferation between <italic>Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup></italic> and <italic>Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup> Eef2k<sup>D273A/D273A</sup></italic> models (<xref ref-type="bibr" rid="bib23">Knight et al., 2020a</xref>). The reversal in proliferation rate with <italic>Eef2k</italic> and <italic>Rpl24<sup>Bst</sup></italic> mutations was also seen in intestinal organoid growth after 3 days (<xref ref-type="fig" rid="fig5">Figure 5D</xref>). Furthermore, inactivation of eEF2K reverted the survival benefit of the <italic>Rpl24<sup>Bst</sup></italic> mutation in the <italic>Apc<sup>fl/+</sup> Kras<sup>G12D/+</sup></italic> tumour model (<xref ref-type="fig" rid="fig5">Figure 5E</xref>). This experiment also shows the lack of effect of the <italic>Eef2k<sup>D273A/D273A</sup></italic> mutation on tumorigenesis. Indeed, <italic>Eef2k<sup>D273A/D273A</sup></italic> had no impact on tumorigenesis in inducible <italic>Apc<sup>fl/+</sup></italic> and germline <italic>Apc<sup>Min/+</sup></italic> models of <italic>Apc</italic>-deficient intestinal tumorigenesis (i.e., expressing wild-type <italic>Kras</italic>) (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B, C</xref>). Consistent with this, the <italic>Eef2k<sup>D273A/D273A</sup></italic> allele had no effect on proliferation in the <italic>Apc<sup>fl/fl</sup></italic> hyperproliferation model, either alone or in combination with <italic>Rpl24<sup>Bst</sup></italic> mutation in both the small intestine and colon (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1D</xref>). Heterozygous inactivation of <italic>Eef2k</italic> resulted in a slight reversal of the extension of survival associated with <italic>Rpl24<sup>Bst</sup></italic> mutation in the <italic>Apc<sup>fl/+</sup> Kras<sup>G12D/+</sup></italic> tumour model (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2A</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Genetic inactivation of <italic>Eef2k</italic> reverses the reduced tumorigenesis following <italic>Rpl24<sup>Bst</sup></italic> mutation in <italic>Apc</italic>-deficient <italic>Kras</italic>-mutant models of colorectal cancer (CRC).</title><p>(<bold>A</bold>) Schematic representation of experimental approach. <italic>Villin<sup>CreER</sup> Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup>, Villin<sup>CreER</sup> Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup> Rpl24<sup>Bst/+</sup></italic>, or <italic>Villin<sup>CreER</sup> Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup> Rpl24<sup>Bst/+</sup> Eef2k<sup>D273A/D273A</sup></italic> mice were induced by intraperitoneal injection of tamoxifen at 80 mg/kg then intestinal tissue analysed 3 days later. Intestines were analysed histologically or processed into intestinal organoids. (<bold>B</bold>) BrdU incorporation quantified from within small intestinal crypt/villus axes following deletion of <italic>Apc</italic> and activation of <italic>Kras</italic>, either wild-type of mutant for <italic>Rpl24</italic>, or mutant for <italic>Rpl24</italic> and <italic>Eef2k</italic>. Data are represented as the mean of at least 20 crypt/villi per mouse ± standard error of the mean (SEM) with significance determined by one-way analysis of variance (ANOVA) with Tukey’s multiple comparison. <italic>N</italic> = 3 per genotype. (<bold>C</bold>) Representative images of H&amp;E, BrdU, and P-eEF2 T56 staining of intestines from the same experiment as (<bold>B</bold>). Red bar on H&amp;E indicates extent of proliferative zone. Bars represent 50 µm. (<bold>D</bold>) Organoids deficient for <italic>Apc</italic> and with activated <italic>Kras</italic> with or without <italic>Rpl24<sup>Bst</sup></italic> mutation, or mutant for both <italic>Rpl24</italic> and <italic>Eef2k</italic> were grown for 3 days and growth relative to day 1 determined by Cell-Titer Blue assay. Data show the mean ± SEM of <italic>n</italic> = 3 biologically independent organoid lines. Significance was determined by one-tailed Mann–Whitney <italic>U</italic> test. (<bold>E</bold>) Survival plot for <italic>Apc Kras</italic> ageing mice with or without the <italic>Rpl24<sup>Bst</sup></italic> mutation, <italic>Eef2K</italic> mutation and with both <italic>Rpl24</italic> and <italic>Eef2k</italic> mutations. Median survival and <italic>n</italic> numbers for each cohort are shown and significance determined by Mantel–Cox test. Censored subjects were removed from the study due to non-intestinal phenotypes. All scale bars are 50 μm.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-69729-fig5-v1.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title><italic>Eef2k<sup>D273A</sup></italic><sup>/D273A</sup> mutation has no effect on tumorigenesis in <italic>Kras</italic> wild-type models.</title><p>(<bold>A</bold>) Scoring for BrdU incorporation in the medial colons of <italic>Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup></italic>, <italic>Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup> Rpl24<sup>Bst/+</sup></italic>, and <italic>Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup> Rpl24<sup>Bst/+</sup> Eef2k<sup>D273A/D273A</sup></italic> mice. Scores are from 3, 4, and 3 mice, respectively, each plotted as the average of at least 20 half crypt/villi. Significance was determined by one-way analysis of variance (ANOVA) with Tukey’s multiple comparison. (<bold>B</bold>) Survival curve from the <italic>Apc<sup>fl/+</sup></italic> tumour model for mice bearing the <italic>Eef2k<sup>D273A/D273A</sup></italic> mutation or wild-type for <italic>Eef2k</italic>. Lack of a significant difference was determined by Mantel–Cox test. (<bold>C</bold>) <italic>Apc<sup>Min/+</sup></italic> tumour model survival curve, for mice with wild-type <italic>Eef2k</italic> or the inactivating mutation, <italic>Eef2k<sup>D273A/D273A</sup></italic>. Lack of a significant difference was determined by Mantel–Cox test. (<bold>D</bold>) Scoring for BrdU-positive cells in the proximal small intestine and medial colons of <italic>Apc<sup>fl/fl</sup></italic>, <italic>Apc<sup>fl/fl</sup> Rpl24<sup>Bst/+</sup></italic>, <italic>Apc<sup>fl/fl</sup> Eef2k<sup>D273A/D273A</sup></italic>, and <italic>Apc<sup>fl/fl</sup> Rpl24<sup>Bst/+</sup> Eef2k<sup>D273A/D273A</sup></italic> mice. Each point on the graphs is plotted as the average of at least 20 half crypt/villi.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-69729-fig5-figsupp1-v1.tif"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 2.</label><caption><title>Heterozygous mutation of <italic>Eef2k<sup>D273A</sup></italic><sup>/+</sup> partially suppresses the effects of <italic>Rpl24<sup>Bst</sup></italic> mutation in the tumour model.</title><p>(<bold>A</bold>) Survival curve from the <italic>Apc<sup>fl/+</sup> Kras<sup>G12D/+</sup></italic> tumour model for mice bearing the <italic>Rpl24<sup>Bst</sup></italic> mutation and/or one copy of the inactivating <italic>Eef2k</italic> mutation. Median survival in days and <italic>n</italic> numbers are shown for each genotype. Significance test was performed by Mantel–Cox test. <italic>Apc<sup>fl/+</sup> Kras<sup>G12D/+</sup></italic> and <italic>Apc<sup>fl/+</sup> Kras<sup>G12D/+</sup> Rpl24<sup>Bst/+</sup></italic> survival curves are reused from <xref ref-type="fig" rid="fig5">Figure 5E</xref>. (<bold>B</bold>) Tumour number (top) and total volume (bottom) scored macroscopically from <italic>Apc<sup>fl/+</sup> Kras<sup>G12D/+</sup></italic> mice with or without <italic>Rpl24<sup>Bst</sup></italic> mutation and with no, one, or two copies of the inactivating <italic>Eef2k<sup>D273A</sup></italic> mutation. Each point is an individual mouse with the bars depicting the mean ± standard error of the mean (standard error of the mean, SEM). From left to right <italic>n</italic> = 20, 11, 14, 9, 18, and 11 mice.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-69729-fig5-figsupp2-v1.tif"/></fig></fig-group><p>Therefore, mutation of <italic>Rpl24</italic> requires functional eEF2K to suppress proliferation and extend survival in this model of CRC. There was no alteration in the number or cumulative size of tumours in the ageing model at endpoint (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2B</xref>), again identifying tumour cell proliferation, rather than tumour initiation, as the principal factor regulated by RPL24 and eEF2K. These data also confirm that the effect of <italic>Rpl24<sup>Bst</sup></italic> mutation on the tumour phenotype is entirely dependent upon eEF2K activity.</p></sec><sec id="s2-6"><title><italic>Rpl24</italic><sup><italic>Bst</italic></sup> mutation suppresses translation exclusively via eEF2K/P-eEF2</title><p>Next, we addressed the molecular consequences of inactivation of eEF2K downstream of <italic>Rpl24<sup>Bst</sup></italic> mutation. The reduction in protein synthesis that results from <italic>Rpl24<sup>Bst</sup></italic> mutation is completely reversed by inactivating eEF2K (<xref ref-type="fig" rid="fig6">Figure 6A</xref>), with <italic>Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup> Rpl24<sup>Bst/+</sup> Eef2k<sup>D273A/D273A</sup></italic> organoids having an almost identical translation capacity as <italic>Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup></italic> controls. Similarly, the rate of ribosome run-off was also reverted in <italic>Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup> Rpl24<sup>Bst/+</sup> Eef2k<sup>D273A/D273A</sup></italic> compared to <italic>Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup> Rpl24<sup>Bst/+</sup></italic> organoids, again to the same rate as controls with wild-type <italic>Rpl24</italic> (<xref ref-type="fig" rid="fig6">Figure 6B</xref> and <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A</xref>). In agreement, crypt fractions from <italic>Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup> Rpl24<sup>Bst/+</sup> Eef2k<sup>D273A/D273A</sup></italic> mice have a reduced, although not significant, the number of heavy polysomes compared to <italic>Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup> Rpl24<sup>Bst/+</sup></italic> crypt cells (<xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2B</xref>), indicating faster translation elongation following eEF2K inactivation.</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Genetic inactivation of <italic>Eef2k</italic> restores translation rates following <italic>Rpl24<sup>Bst</sup></italic> mutation.</title><p>(<bold>A</bold>) <sup>35</sup>S-methionine incorporation to determine relative protein synthesis by in <italic>Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup></italic> small intestinal organoids wild-type or mutant for <italic>Rpl24</italic> or with both <italic>Rpl24</italic> andConsistent with this, the <italic>Eef2k</italic> mutations. Data are represented ± standard error of the mean (standard error of the mean, SEM) with significance determined by one-way analysis of variance (ANOVA) with Tukey’s multiple comparison. <italic>N</italic> = 3 per genotype, each representing an independent organoid line. (<bold>B</bold>) Ribosome run-off rate determined in <italic>Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup></italic> small intestinal organoids mutant or wild-type for <italic>Rpl24</italic> or with both <italic>Rpl24</italic> and <italic>Eef2k</italic> mutations. Data are the mean of three biologically independent organoid lines represented ± SEM with significance determined by Mann–Whitney <italic>U</italic> test. Raw data are available in <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A</xref>. The run-off rate for <italic>Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup></italic> control organoids is reproduced from <xref ref-type="fig" rid="fig3">Figure 3E</xref>. (<bold>C</bold>) Schematic representation of findings in <italic>Apc</italic>-deficient <italic>Kras-</italic>mutant mouse and organoid models. Top: RPL24 expression maintains translation and proliferation by suppressing the phosphorylation of eEF2 by limiting eEF2K activity. Middle: reduced expression of RPL24 activates eEF2K, increasing P-eEF2, reducing translation elongation and suppressing tumorigenesis and proliferation. Bottom: inactivation of eEF2K reverts the phenotype in <italic>Rpl24<sup>Bst</sup></italic> cells, due to the inability to phosphorylate and suppress eEF2. Elevated elongation rates correlate with increased proliferation following inactivation of eEF2K.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-69729-fig6-v1.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Inactivation of <italic>Eef2k</italic> restores translation elongation speed in <italic>Rpl24<sup>Bst</sup></italic> mutant mice.</title><p>(<bold>A</bold>) Polysome profiles from sucrose density gradients of <italic>Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup> Rpl24<sup>Bst/+</sup></italic> or <italic>Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup> Rpl24<sup>Bst/+</sup> Eef2k<sup>D273A/D273A</sup></italic> small intestinal organoid cultures, pre-treated with harringtonine for 5 min/300 s (H300) or untreated (H0). These traces are representative of those analysed for the run-off rates shown in <xref ref-type="fig" rid="fig6">Figure 6B</xref>. (<bold>B</bold>) Representative sucrose density profiles generated from <italic>Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup></italic> intestinal extracts with or without the <italic>Rpl24<sup>Bst</sup></italic> mutation and inactivation of eEF2K. Subpolysomal components and polysomes are labelled, and the polysomes have been split pictorially into light and heavy. To the right of this is quantification of the heavy:light polysome ratio. Data show the mean ± standard error of the mean (standard error of the mean, SEM) of 5, 3, and 3 mice reading from left to right. Significance was determined by one-way analysis of variance (ANOVA) with Tukey’s multiple comparison.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-69729-fig6-figsupp1-v1.tif"/></fig><fig id="fig6s2" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 2.</label><caption><title><italic>Rpl24<sup>Bst</sup></italic> mutation has no effect on P-ERK or P-ACC.</title><p>(<bold>A</bold>) Immunohistochemistry (IHC) staining for P-ERK T202/T204 in intestinal tissue form <italic>Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup></italic> or <italic>Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup> Rpl24<sup>Bst/+</sup></italic> mice. Representative images from each genotype are shown on the right and <italic>H</italic>-score quantification from three animals per genotype on the left. (<bold>B</bold>) Western blotting on lysates from <italic>Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup></italic> or <italic>Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup> Rpl24<sup>Bst/+</sup></italic> organoids, for P-ACC S79, ACC, and β-actin as a sample control. All scale bars are 50 μm.</p><p><supplementary-material id="fig6s2sdata1"><label>Figure 6—figure supplement 2—source data 1.</label><caption><title>Left: data from <xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2B</xref>.</title><p>Right: original western blotting images with areas for each antibody annotated and boxed in red.</p></caption><media mime-subtype="pdf" mimetype="application" xlink:href="elife-69729-fig6-figsupp2-data1-v1.pdf"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-69729-fig6-figsupp2-v1.tif"/></fig></fig-group><p>This has important implications for the function of RPL24, showing that ribosomes in <italic>Rpl24<sup>Bst</sup></italic> mutant cells can elongate efficiently despite the reduction in RPL24 expression. However, reduced RPL24 increases P-eEF2 which inhibits elongation, with an absolute requirement for eEF2K for this (<xref ref-type="fig" rid="fig6">Figure 6C</xref>). Importantly, the combination of the <italic>Rpl24</italic> and <italic>eEF2K</italic> mutants shows that when P-eEF2 is abolished elongation occurs at normal speed, despite reduced expression of RPL24.</p><p>eEF2K activity is regulated by several upstream signalling pathways, as well as factors such as calcium ion and oxygen levels (<xref ref-type="bibr" rid="bib1">Ballard et al., 2021</xref>). Given that the <italic>Rpl24<sup>Bst</sup></italic> mutation increases phosphorylation of P-eEF2, we assessed what effect the mutation had on multiple kinases upstream of eEF2K in <italic>Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup></italic> and <italic>Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup> Rpl24<sup>Bst/+</sup></italic> small intestinal tissue and organoids. mTORC1 suppresses eEF2K activity via p70 S6K. However, we saw no difference in the mTORC1-regulated phosphorylation of RPS6 (S240/4) and 4E-BP1 (T37/46) (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). Similarly, MAPK signalling also suppresses eEF2K, via the RSK pathway. There was no difference in signalling through this pathway in <italic>Rpl24</italic> mutant mice, as assayed via P-ERK1/2 (T202/Y204) (<xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2A</xref>). AMPK directly phosphorylates and activates eEF2K in response to changes in intracellular ATP:AMP ratio. Using phosphorylation of the canonical AMPK target acetyl-CoA carboxylase (P-ACC S79) as a read-out of AMPK activity, <italic>Rpl24</italic> mutation had no effect on AMPK signalling (<xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2B</xref>). Thus, we find no evidence for RPL24 expression levels affecting the activity of three kinases that in turn regulate eEF2K.</p></sec><sec id="s2-7"><title>The expression of <italic>RPL24, EEF2K, and EEF2</italic> is indicative of fast elongation in human CRC</title><p>Using pre-clinical mouse models, we have demonstrated that physiological RPL24 expression maintains low eEF2K-mediated phosphorylation of eEF2 (<xref ref-type="fig" rid="fig7">Figure 7A</xref>). Hypo-phosphorylated eEF2 then ensures rapid protein synthesis enabling tumour proliferation in vivo. We next sought to position this pre-clinical work in the context of clinical studies of the human disease. Using publicly available datasets for RNA expression in normal and cancerous colon tissues we observe increased <italic>RPL24</italic> and <italic>EEF2</italic> expression in conjunction with reduced <italic>EEF2K</italic> expression (<xref ref-type="fig" rid="fig7">Figure 7B</xref>). This mirrors the signalling pathways in our mouse models and ensures high expression of active eEF2. Elevated <italic>EEF2</italic> message and reduced <italic>EEF2K</italic> message levels in these clinical samples are consistent with conservation of this signalling in the clinic. Similar results are seen for the protein expression of RPL24, eEF2K, and eEF2 from colon adenocarcinoma samples (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1A</xref>), and for the three mRNAs in rectal adenocarcinoma (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1B</xref>). These expression analyses highlight the conservation of the proliferative tumour-associated signalling pathways characterised in our pre-clinical mouse models and patient samples.</p><fig-group><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Expression of <italic>RPL24</italic>, <italic>EEF2K</italic>, and <italic>EEF2</italic> is consistent with increased eEF2 activity in colorectal cancer (CRC) tumours.</title><p>(<bold>A</bold>) Schematic of the findings presented here from pre-clinical mouse models. KRAS activation requires RPL24 expression to maintain low eEF2 phosphorylation. This occurs via a double negative regulation of eEF2K, whereby RPL24 suppresses eEF2K, which suppresses eEF2. eEF2 activity correlates with protein synthesis and proliferation rates. Dashed lines indicate indirect or undefined regulatory pathways. (<bold>B</bold>) RNA expression levels of <italic>RPL24</italic>, <italic>EEF2K</italic>, and <italic>EEF2</italic> between normal colon and colon adenocarcinoma samples using data extracted from The Cancer Genome Atlas by TNMplot. Relative expression changes are annotated, as well as p values for each transcript.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-69729-fig7-v1.tif"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 1.</label><caption><title>Expression of <italic>RPL24</italic>, <italic>EEF2K</italic>, and <italic>EEF2</italic> suggest increased eEF2 activity in colorectal cancer (CRC) tumours.</title><p>(<bold>A</bold>) Protein levels of RPL24, eEF2K, and eEF2 in normal colon and colon adenocarcinoma collated from the Clinical Proteomic Tumor Analysis Consortium by UALCAN. Numbers of samples and p values are shown for each protein. (<bold>B</bold>) RNA expression levels of <italic>RPL24</italic>, <italic>EEF2K</italic>, and <italic>EEF2</italic> between normal rectum and rectum adenocarcinoma samples using data extracted from The Cancer Genome Atlas by TNMplot. Relative expression changes are annotated, as well as p values for each transcript.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-69729-fig7-figsupp1-v1.tif"/></fig></fig-group></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>The original characterisation of the <italic>Rpl24<sup>Bst</sup></italic> mutation identified a defect in ribosome biogenesis affecting the synthesis of 60S subunits (<xref ref-type="bibr" rid="bib31">Oliver et al., 2004</xref>). The evidence to support this was limited to analyses of fasted/refed mouse livers for nascent rRNAs and by polysome profiles purporting to show reductions in 28S rRNA precursors and mature 60S subunits, respectively. In contrast, RNAi depletion of RPL24 in human cell lines had no effect on ribosome biogenesis, or on the relative abundance of 40S and 60S subunits (<xref ref-type="bibr" rid="bib2">Barkić et al., 2009</xref>; <xref ref-type="bibr" rid="bib46">Wilson-Edell et al., 2014</xref>). Furthermore, two reports have identified RPL24 as an exclusively cytoplasmic protein, leading to the hypothesis that it is assembled into mature ribosomes in the cytoplasm after rRNA synthesis and processing has already occurred (<xref ref-type="bibr" rid="bib2">Barkić et al., 2009</xref>; <xref ref-type="bibr" rid="bib38">Saveanu et al., 2003</xref>). In agreement with this, in the hindbrain of E9.5 embryos, the <italic>Rpl24<sup>Bst</sup></italic> mutation had no effect on nucleolar architecture, indicating that it is not required for nucleolar function (<xref ref-type="bibr" rid="bib15">Herrlinger et al., 2019</xref>). Our data agree with these later examples, as we fail to see any effect of the <italic>Rpl24<sup>Bst</sup></italic> mutation on 60S:40S ratio in wild-type or transformed mouse intestines. Of further importance to the field, we also demonstrate in our tumour model that the translation defect in <italic>Rpl24<sup>Bst</sup></italic> mutant mice is restored to normal levels following inactivation of eEF2K in <italic>Rpl24<sup>Bst</sup></italic> mutant mice, showing that the defect is dependent on eEF2K. From this, we conclude that although the ribosomes produced in <italic>Rpl24<sup>Bst/+</sup></italic> mice do allow protein synthesis to proceed at near physiological levels, this process is restricted via signalling through eEF2K/P-eEF2.</p><p>RPL24 depletion suppresses tumorigenesis in <italic>Apc</italic>-deficient <italic>Kras</italic>-mutant (APC KRAS) mouse models of CRC, but not in <italic>Apc</italic>-deficient <italic>Kras</italic> wild-type (APC) models. In line with this, protein synthesis is reduced following depletion of RPL24 in our APC KRAS models, but not in APC models, despite induction of P-eEF2 in both cases. We previously showed that suppression of translation elongation via mTORC1/eEF2K/P-eEF2, using rapamycin, in the same APC models dramatically suppressed proliferation and extended survival (<xref ref-type="bibr" rid="bib10">Faller et al., 2015</xref>). Thus, while RPL24 depletion or rapamycin treatment of <italic>Apc</italic>-deficient intestines each induce P-eEF2, only rapamycin treatment suppresses protein synthesis. The effect on protein synthesis appears to be the differential driving this divergence, with proliferation only impaired when protein synthesis is reduced. Crucially, RPL24 deficiency does not suppress mTORC1 activity since phosphorylation of the mTORC1 effectors 4E-BP1 and RPS6 (at S240/S244) is not reduced in <italic>Apc</italic>-deficient <italic>Rpl24<sup>Bst/+</sup></italic> intestines, providing an explanation of how proliferation and protein synthesis are maintained in <italic>Apc</italic>-deficient <italic>Rpl24<sup>Bst</sup></italic> mutant animals. We also provide evidence that <italic>Rpl24</italic> expression is lower than that of other ribosomal protein mRNAs following <italic>Kras</italic> mutation, which could explain why diminished RPL24 expression specifically suppresses proliferation in <italic>Kras</italic>-mutant models.</p><p>In view of the mechanisms we have described here, it is interesting to reflect on previous work with the <italic>Rpl24<sup>Bst</sup></italic> mutant mouse. The <italic>Rpl24<sup>Bst</sup></italic> mutation suppresses tumorigenesis in three mouse models of different types of blood cancer, and in a model of bladder cancer (<xref ref-type="bibr" rid="bib40">Signer et al., 2014</xref>; <xref ref-type="bibr" rid="bib3">Barna et al., 2008</xref>; <xref ref-type="bibr" rid="bib17">Hsieh et al., 2010</xref>; <xref ref-type="bibr" rid="bib19">Jana et al., 2021</xref>). In each case, the <italic>Rpl24<sup>Bst</sup></italic> mutation was found to decrease translation, although how the translation was suppressed was not fully determined. Barna et al. demonstrated a reduction in cap-dependent translation using a luciferase reporter in <italic>Rpl24<sup>Bst</sup></italic> MEFs (<xref ref-type="bibr" rid="bib3">Barna et al., 2008</xref>). Furthermore, <italic>Rpl24<sup>Bst</sup></italic> mutation dramatically suppressed translation following MYC activation, consistent with <italic>Rpl24<sup>Bst</sup></italic> slowing tumorigenesis via reduced translation. We have shown that in mouse models of CRC the molecular mechanism by which normal levels of RPL24 maintain translation is via eEF2K and P-eEF2, therefore implicating this pathway in these previously studied blood cancer models.</p><p>The <italic>Rpl24<sup>Bst</sup></italic> mutation has also been used to analyse brain development from neural progenitor cells and explored as a model for retinal degenerative disease (<xref ref-type="bibr" rid="bib33">Riazifar et al., 2015</xref>; <xref ref-type="bibr" rid="bib15">Herrlinger et al., 2019</xref>). These studies found a revertant phenotype in neural progenitor cells overexpressing LIN28A and a defect in subretinal angiogenesis in <italic>Rpl24<sup>Bst/+</sup></italic> mice. The role of translation elongation should now be analysed with respect to these phenotypes. eEF2K, and the many upstream pathways it integrates, are potential targets for intervention in these in vivo models. It will also be of interest to determine how the inactivation of eEF2K affects the whole-body phenotypes of the <italic>Rpl24<sup>Bst</sup></italic> mouse, such as the coat pigmentation and tail defects.</p><p>eEF2K has a pleiotropic effect in tumorigenesis, acting akin to a tumour suppressor or promoter dependent on the context (<xref ref-type="bibr" rid="bib24">Knight et al., 2020b</xref>). In some cancers, eEF2K promotes tumorigenesis. For example, under nutrient deprivation eEF2K acts as a pro-survival factor in transformed fibroblasts and tumour cell lines by suppressing protein synthesis to ensure survival (<xref ref-type="bibr" rid="bib26">Leprivier et al., 2013</xref>). Here, we show that eEF2K inactivation does not modify intestinal tumorigenesis. However, eEF2K is required for the suppression of tumorigenesis and protein synthesis following mTORC1 inhibition in APC cells (<xref ref-type="bibr" rid="bib10">Faller et al., 2015</xref>) or <italic>Rpl24<sup>Bst</sup></italic> mutation in APC KRAS cells (this work). Therefore, although eEF2K does not directly drive tumorigenesis, low eEF2K activity ensures there is no blockade of translation or proliferation in tumour cells. Furthermore, eEF2K expression is required for drug or signalling responses that suppress tumorigenesis, giving it tumour suppressive activity. In accordance, CRC patients with low eEF2K protein expression suffer a significantly worse prognosis (<xref ref-type="bibr" rid="bib30">Ng et al., 2019</xref>). Furthermore, we present mRNA and protein expression data showing that eEF2K is reduced in clinical CRC samples compared to normal tissue. This agrees with a model where low eEF2K allows rapid translation elongation to promote proliferation.</p><p>Using the same clinical datasets we demonstrate that both RPL24 and eEF2 are elevated in CRC, consistent with their roles in promoting translation and proliferation. This presents the possibility of directly targeting either RPL24 or eEF2 for anti-cancer benefit. In agreement with this, RNAi against RPL24 in human breast cancer cell lines dramatically reduced proliferation (<xref ref-type="bibr" rid="bib46">Wilson-Edell et al., 2014</xref>). Similarly, inhibiting eEF2, using a compound reported to slow its exit from the ribosome and thus the rate of protein synthesis, reduces cell line and patient derived organoid growth (<xref ref-type="bibr" rid="bib44">Stickel et al., 2015</xref>; <xref ref-type="bibr" rid="bib20">Keysar et al., 2020</xref>). These reports agree with the data presented here suggesting that targeting of RPL24 or eEF2 would be beneficial in CRC. Identifying the mechanistic link between RPL24 and eEF2K is part of our ongoing work, but here we have ruled out mTORC1, MAPK, and AMPK signalling as contributing factors.</p><p>This work uncovers an unexpected role for the ribosomal protein RPL24 in the regulation of translation elongation, acting via eEF2K/P-eEF2. We demonstrate that depletion of RPL24 suppresses tumorigenesis in a pre-clinical mouse model of a CRC. We provide genetic evidence supported by molecular assays of translation elongation to demonstrate that RPL24 depletion activates eEF2K to elicit tumour suppression in our models. We also speculate as to the role of eEF2K in the previously published blood cancer models where RPL24 depletion was beneficial. This work provides additional evidence for the anti-tumorigenic role of eEF2K in CRC, highlighting the potential for targeting translation elongation for this disease.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Genetic reagent (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">Tg(Vil1-cre/<break/>ERT2)23Syr</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib9">el Marjou et al., 2004</xref></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:MGI:3053826">MGI:3053826</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">Apc<sup>tm1Tno</sup></td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib39">Shibata et al., 1997</xref></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:MGI:1857966">MGI:1857966</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">Kras<sup>tm4Tyj</sup></td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib18">Jackson et al., 2001</xref></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:MGI:2429948">MGI:2429948</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">Rpl24<sup>Bst</sup></td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib31">Oliver et al., 2004</xref></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:MGI:1856685">MGI:1856685</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">Eef2k<sup>D273A</sup></td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib13">Gildish et al., 2012</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">Apc<sup>Min</sup></td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib27">Moser et al., 1990</xref></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:MGI:1856318">MGI:1856318</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">Villin<sup>CreER</sup> <italic>Apc<sup>fl/fl</sup> <break/>Kras<sup>G12D/+</sup></italic> small <break/>intestinal organoids</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">Villin<sup>CreER</sup> <italic>Apc<sup>fl/fl</sup></italic> <break/>small intestinal <break/>organoids</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">Villin<sup>CreER</sup> <italic>Apc<sup>fl/fl</sup> <break/>Kras<sup>G12D/+</sup> <break/>Rpl24<sup>Bst/+</sup></italic> small <break/>intestinal organoids</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">Villin<sup>CreER</sup> <italic>Apc<sup>fl/fl</sup> <break/>Rpl24<sup>Bst/+</sup></italic> small <break/>intestinal organoids</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">BrdU(mouse <break/>monoclonal)</td><td align="left" valign="bottom">BD Biosciences <break/>#347,580</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_400326">AB_400326</ext-link></td><td align="left" valign="bottom">IHC: (1:250)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">P-eEF2 T56(rabbit <break/>polyclonal)</td><td align="left" valign="bottom">Cell Signaling <break/>Technology #2,331</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10015204">AB_10015204</ext-link></td><td align="left" valign="bottom">WB: (1:2000)IHC: (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">eEF2(rabbit <break/>polyclonal)</td><td align="left" valign="bottom">Cell Signaling <break/>Technology #2,332</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10693546">AB_10693546</ext-link></td><td align="left" valign="bottom">WB: (1:2000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">P-4E-BP1(rabbit <break/>monoclonal)</td><td align="left" valign="bottom">Cell Signaling <break/>Technology #2,855</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_560835">AB_560835</ext-link></td><td align="left" valign="bottom">IHC: (1:250)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">P-RPS6 S240/4(rabbit <break/>monoclonal)</td><td align="left" valign="bottom">Cell Signaling <break/>Technology #5,364</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10694233">AB_10694233</ext-link></td><td align="left" valign="bottom">IHC: (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">P-eIF2α S51(rabbit <break/>monoclonal)</td><td align="left" valign="bottom">Cell Signaling <break/>Technology#3,398</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2096481">AB_2096481</ext-link></td><td align="left" valign="bottom">IHC: (1:50)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">P-ERK T202/<break/>Y204(rabbit <break/>polyclonal)</td><td align="left" valign="bottom">Cell Signaling <break/>Technology #9,101</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_331646">AB_331646</ext-link></td><td align="left" valign="bottom">IHC: (1:400)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Lysozyme(rabbit polyclonal)</td><td align="left" valign="bottom">Dako A0099</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2341230">AB_2341230</ext-link></td><td align="left" valign="bottom">IHC: (1:300)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">RPS6(mouse <break/>monoclonal)</td><td align="left" valign="bottom">Cell Signaling <break/>Technology #2,317</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2238583">AB_2238583</ext-link></td><td align="left" valign="bottom">WB: (1:2000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">RPL10(rabbit <break/>polyclonal)</td><td align="left" valign="bottom">Novus <break/>NBP1-84037</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_11007661">AB_11007661</ext-link></td><td align="left" valign="bottom">WB: (1:2000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">RPL22(rabbit <break/>polyclonal)</td><td align="left" valign="bottom">Abcam <break/>ab111073</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10863642">AB_10863642</ext-link></td><td align="left" valign="bottom">WB: (1:2000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Acetyl-CoA <break/>carboxylase(rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling <break/>Technology #3,676</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2219397">AB_2219397</ext-link></td><td align="left" valign="bottom">WB: (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">P-acetyl-CoA <break/>carboxylase <break/>S79(rabbit <break/>monoclonal)</td><td align="left" valign="bottom">Cell Signaling <break/>Technology #3,661</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_330337">AB_330337</ext-link></td><td align="left" valign="bottom">WB: (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">β-Actin(mouse <break/>monoclonal)</td><td align="left" valign="bottom">Sigma-Aldrich <break/>#A2228</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_476697">AB_476697</ext-link></td><td align="left" valign="bottom">WB: (1:10,000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">β-Tubulin(mouse <break/>monoclonal)</td><td align="left" valign="bottom">Cell Signaling <break/>Technology #2,128</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_823664">AB_823664</ext-link></td><td align="left" valign="bottom">WB: (1:4000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Goat Anti-Mouse Immunoglobulins/<break/>HRP(goat polyclonal)</td><td align="left" valign="bottom">Dako #P0447</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2617137">AB_2617137</ext-link></td><td align="left" valign="bottom">WB: (1:2000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Goat Anti-Rabbit Immunoglobulins/<break/>HRP(goat polyclonal)</td><td align="left" valign="bottom">Dako #P0448</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2617138">AB_2617138</ext-link></td><td align="left" valign="bottom">WB: (1:2000)</td></tr><tr><td align="left" valign="bottom">Sequence-<break/>based reagent</td><td align="left" valign="bottom"><italic>Olfm4</italic> RNAScope</td><td align="left" valign="bottom">ACD #311,838</td><td align="left" valign="bottom">RNAScope</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, <break/>recombinant <break/>protein</td><td align="left" valign="bottom">Recombinant <break/>Murine Noggin</td><td align="left" valign="bottom">Peprotech #250-38</td><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">100 ng/ml</td></tr><tr><td align="left" valign="bottom">Peptide, <break/>recombinant <break/>protein</td><td align="left" valign="bottom">Animal-Free <break/>Recombinant <break/>Human EGF</td><td align="left" valign="bottom">Peprotech <break/>#AF-100-15</td><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">50 ng/ml</td></tr><tr><td align="left" valign="bottom">Peptide, <break/>recombinant <break/>protein</td><td align="left" valign="bottom">Recombinant <break/>Mouse R-Spondin <break/>1 Protein</td><td align="left" valign="bottom">R&amp;D Systems <break/>#3474-RS</td><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">500 ng/ml</td></tr><tr><td align="left" valign="bottom">Commercial <break/>assay or kit</td><td align="left" valign="bottom">Vectorstain Elite <break/>ABC-HRP</td><td align="left" valign="bottom">Vector Laboratories PK-6102</td><td align="left" valign="bottom">RRIDs:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:AB_2336820">AB_2336820</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial <break/>assay or kit</td><td align="left" valign="bottom">Vectorstain Elite <break/>ABC-HRP</td><td align="left" valign="bottom">Vector Laboratories <break/>PK-PK-6101</td><td align="left" valign="bottom">RRIDs:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:AB_2336821">AB_2336821</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial <break/>assay or kit</td><td align="left" valign="bottom">Cell Proliferation <break/>Labelling Reagent</td><td align="left" valign="bottom">Amersham <break/>Bioscience RPN201</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial <break/>assay or kit</td><td align="left" valign="bottom">Cell-Titer Blue</td><td align="left" valign="bottom">Promega #G8080</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical <break/>compound, <break/>drug</td><td align="left" valign="bottom">Rapamycin</td><td align="left" valign="bottom">LC Laboratories <break/>#R-5000</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical <break/>compound, <break/>drug</td><td align="left" valign="bottom">Harringtonine</td><td align="left" valign="bottom">Santa Cruz <break/>sc-204771</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical <break/>compound, <break/>drug</td><td align="left" valign="bottom">EasyTag EXPRESS <break/><sup>35</sup>S Protein <break/>Labeling Mix</td><td align="left" valign="bottom">Perkin Elmer #NEG772002MC</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">software, <break/>algorithm</td><td align="left" valign="bottom">Image J</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib36">Rueden et al., 2017</xref></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_003070">SCR_003070</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">software, <break/>algorithm</td><td align="left" valign="bottom">G*Power</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib11">Faul et al., 2009</xref></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_013726">SCR_013726</ext-link></td><td align="left" valign="bottom"/></tr></tbody></table></table-wrap><sec id="s4-1"><title>Materials availability</title><p>The mouse strains used will be made available on request. However, this may require a Materials Transfer Agreement and/or a payment if there is potential for commercial application. We ourselves are limited by the terms of Materials Transfer Agreements agreed to by the suppliers of the mouse strains.</p></sec><sec id="s4-2"><title>Mouse studies</title><p>Experiments with mice were performed under licence from the UK Home Office (licence numbers 60/4183 and 70/8646). All mice used were inbred C57BL/6J (Generation ≥8) and were housed in conventional cages with a 12 hr light/dark cycle and ad libitum access to diet and water. Mice were genotyped by Transnetyx in Cordova, Tennessee. Experiments were performed on mice between the ages of 6 and 12 weeks; both male and female mice were used. Sample sizes for all experiments were calculated using the G*Power software (<xref ref-type="bibr" rid="bib11">Faul et al., 2009</xref>) and are shown in the figures or legends. Researchers were not blinded during experiments. The <italic>Villin<sup>CreER</sup></italic> allele (<xref ref-type="bibr" rid="bib9">el Marjou et al., 2004</xref>) was used for intestinal recombination by intraperitoneal (IP) injection of tamoxifen in corn oil at a final in vivo concentration of 80 mg/kg. The <italic>Apc</italic> flox allele, <italic>Apc<sup>Min</sup></italic>, <italic>Kras<sup>G12D</sup></italic> lox-STOP-lox allele, <italic>Eef2k<sup>D273A</sup></italic> and <italic>Rpl24<sup>Bst</sup></italic> alleles were previously described (<xref ref-type="bibr" rid="bib18">Jackson et al., 2001</xref>; <xref ref-type="bibr" rid="bib39">Shibata et al., 1997</xref>; <xref ref-type="bibr" rid="bib13">Gildish et al., 2012</xref>; <xref ref-type="bibr" rid="bib31">Oliver et al., 2004</xref>; <xref ref-type="bibr" rid="bib27">Moser et al., 1990</xref>). Tumour model experiments began with a single dose of tamoxifen after which mice were monitored until they showed signs of intestinal disease – paling feet from anaemia, weight loss and hunching behaviour. Tumours were scored macroscopically by counting and recording diameter after fixation of intestinal tissue. Tumour volumes were calculated from the tumour diameters assuming a spherical tumour shape. For short-term experiments, mice wild-type for <italic>Kras</italic> were induced on consecutive days (days 0 and 1) and sampled 4days after the first induction (day 4). Mice bearing the <italic>Kras<sup>G12D</sup></italic> allele were induced once and sampled on day 3 post-induction. Where indicated, 250 μl of BrdU cell proliferation labelling reagent (Amersham Bioscience RPN201) was given by IP injection 2 hr prior to sampling. BrdU-positive cells were scored from crypt base to villus tip (a half crypt/villus axis) from the proximal small intestine or medial colon and represented as the mean number of positive cells from at least 20 axes per mouse. For the regeneration experiments, mice were exposed to 10 Gy of γ-irradiation at a rate of 0.423 Gy/min from a caesium 137 source. They were then sampled 72 hr after irradiation and regenerative crypts scored from H&amp;E stained sections as previously described (<xref ref-type="bibr" rid="bib10">Faller et al., 2015</xref>). Batch correction was used by normalising each experiment to relevant wild-type controls.</p></sec><sec id="s4-3"><title>Histology and IHC</title><p>Tissue was fixed in formalin and embedded in paraffin. IHC staining was carried out as previously (<xref ref-type="bibr" rid="bib10">Faller et al., 2015</xref>), using the following antibodies: BrdU (BD Biosciences #347580), P-eEF2 T56 (Cell Signaling Technology [CST] #2331), P-4E-BP1 T37/46 (CST #2855), P-RPS6 S240/4 (CST #5364), P-eIF2α S51 (CST #3398), P-ERK T202/Y204 (CST #9101), RPL24 (Sigma-Aldrich HPA051653), and Lysozyme (Dako A0099). The IHC protocol followed the Vector ABC kit (mouse #PK-6102, rabbit #PK-6101). RNAScope analysis was conducted according to the manufacturer’s guidelines (ACD) using a probe to murine <italic>Olfm4</italic> (#311838). For all staining, a minimum of three biological replicates were stained and representative images used throughout. For BrdU scoring in short-term model experiments tissue was fixed in methanol:chloroform:acetic acid at a ratio 4:2:1 then transferred to formalin and embedded in paraffin.</p></sec><sec id="s4-4"><title>Intestinal organoid culture</title><p>Crypt cultures were isolated and then maintained as previously described (<xref ref-type="bibr" rid="bib23">Knight et al., 2020a</xref>). In all crypt culture experiments, multiple biologically independent cultures were generated and analysed from different animals of the shown genotypes. DMEM/F12 medium (Life Technologies #12634-028) was supplemented with 5 mM HEPES (Life Technologies #15630-080), 100 U/ml penicillin/streptomycin (Life Technologies #1540-122), 2 mM <sc>L</sc>-glutamine (Life Technologies #25030-024), 1× N2, 1× B27 (Invitrogen #17502-048 and #12587-010), 100 ng/ml noggin (Peprotech #250-38), and 50 ng/ml EGF (Peprotech #AF-100-15). Wild-type cultures were also supplemented with 500 ng/ml R-spondin (R&amp;D Systems #3474-RS). For ex vivo growth assays, cells were plated in technical triplicate in 96-well plates, and proliferation measured using Cell-Titer Blue (Promega #G8080) added to previously untreated cells each day for up to 4 days. Rapamycin (LC Laboratories R-5000) was dissolved in DMSO and administered for 24 hr, comparing to DMSO vehicle-treated cells.</p></sec><sec id="s4-5"><title>Western blotting</title><p>Samples were lysed (10 mM Tris [pH 7.5], 50 mM NaCl, 0.5% NP40, 0.5% SDS supplemented with protease inhibitor cocktail [Roche #11836153001] PhosSTOP [Roche #04906837001] and benzonase [Sigma-Aldrich #E1014]) on ice and then the protein content estimated by BCA assay (Thermo Fisher Scientific #23225). 20 μg of protein were denatured in loading dye containing SDS then resolved by 4–12% sodium dodecyl sulphate–polyacrylamide gel electrophoresis (Invitrogen #NP0336BOX). For western blots from gradients, equivalent volumes were loaded from each gradient fraction. Protein was transferred to nitrocellulose membranes, blocked with excess protein and immunoblotted overnight at 4°C using the following antibodies; P-eEF2 T56 (CST #2331), eEF2 (CST #2332), RPL24 (Sigma-Aldrich HPA051653), RPS6 (CST #2317), RPL10 (Novus NBP1-84037), RPL22 (Abcam ab111073), ACC (CST #3676), P-ACC S79 (CST #3661), β-tubulin (CST #2128), and β-actin (Sigma-Aldrich #A2228) as a sample control. One-hour incubation at room temperature with secondary antibodies (horseradish peroxidase [HRP]-conjugated anti-mouse secondary [Dako #P0447]; HRP-conjugated anti-rabbit secondary [Dako #P0448]) was followed by exposure to autoradiography films or a ChemiDoc MP imager (BioRad) with ECL reagent (Thermo Fisher Scientific #32106). Quantification was performed using Image J (<xref ref-type="bibr" rid="bib36">Rueden et al., 2017</xref>).</p></sec><sec id="s4-6"><title>Sucrose density gradients</title><p>Cells were replenished with fresh medium for the 6 hr before harvesting. This medium was then spiked with 200 µg/ml cycloheximide (Sigma-Aldrich #C7695) 3 min prior to harvesting on ice. Crypt fractions from mice were isolated by extraction of the epithelium from 10 cm of proximal small intestine. Each data point plotted represents an individual animal. PBS-flushed linearly opened small intestines were incubated in RPMI 1640 medium (Thermo Fisher Scientific #21875059) supplemented with 10 mM EDTA and 200 µg/ml cycloheximide for 7 min at 37°C with regular agitation to extract villi. Crypts were isolated by transferring remaining tissue to ice-cold PBS containing 10 mM EDTA and 200 µg/ml cycloheximide for a further 7 min, again with agitation. The remaining tissue was discarded. Samples were lysed (300 mM NaCl, 15 mM MgCl2, 15 mM Tris pH 7.5, 100 µg/ml cycloheximide, 0.1% Triton X-100, 2 mM DTT, and 5 U/ml SUPERase.In RNase Inhibitor (Thermo Fisher Scientific #AM2696)) on ice and post-nuclear extracts placed on top of 10–50% wt/vol sucrose gradients containing the same buffer (apart from no Triton X-100, DTT, or SUPERase.In). These were then spun in an SW40Ti rotor at 255,000 rcf for 2 hr at 4°C under a vacuum. Samples were then separated through a live 254 nM optical density reader (ISCO). Polysome to subpolysome (P:S), heavy to light polysome (H:L), or 60S to 40S (60S:40S) ratios were calculated using the manually defined trapezoid method. For harringtonine run-off assays, cultures were prepared in duplicate for each genotype. One was pre-treated with 2 µg/ml harringtonine (Santa Cruz sc-204771) for 5 min (300 s) prior to cycloheximide addition. This was then processed as above. Run-off rates were calculated as previously described (<xref ref-type="bibr" rid="bib22">Knight et al., 2015</xref>). Trichloroacetic acid protein precipitation from sucrose density gradients was performed as before (<xref ref-type="bibr" rid="bib21">Knight et al., 2013</xref>).</p></sec><sec id="s4-7"><title><sup>35</sup>S-methionine incorporation assay</title><p>Organoids were replenished with medium 6 hr prior to analysis while in the optimal growth phase post-splitting. Technical triplicates were used from organoids from three different animals per experiments. <sup>35</sup>S-methionine (Perkin Elmer #NEG772002MC) was used at 30 µCi/ml for 30 min. Samples were lysed using the same buffer described for Western blotting. Protein was precipitated in 12.5% (wt/vol) trichloroacetic acid onto glass microfiber paper (Whatmann #1827-024) by use of a vacuum manifold. Precipitates were washed with 70% ethanol and acetone. Scintillation was read on a Wallac MicroBeta TriLux 1450 scintillation counter using Ecoscint scintillation fluid (SLS Ltd #LS271) from these microfiber papers. In parallel the total protein content was determined by BCA assay using unprecipitated sample. Protein synthesis rate was expressed as the scintillation normalised to the total protein content (CPM/µg/ml protein), which was then changed to a relative value compared to relevant controls for each experiment.</p></sec><sec id="s4-8"><title>RNA sequencing</title><p>This was performed as previously described (<xref ref-type="bibr" rid="bib23">Knight et al., 2020a</xref>), using three animals per genotype. The reads for each ribosomal protein mRNA were then averaged and the fold change compared to wild-type tissue calculated and plotted. Source data for this analysis are available linked to <xref ref-type="fig" rid="fig4">Figure 4F</xref>.</p></sec><sec id="s4-9"><title>Publicly available clinical data analysis</title><p>The TNMplot and UALCAN web portals were used to analysis publicly available dataset from The Cancer Genome Atlas and Clinical Proteomic Tumor Analysis Consortium. Details of these portals are available in these publications (<xref ref-type="bibr" rid="bib4">Bartha and Győrffy, 2021</xref>; <xref ref-type="bibr" rid="bib7">Chandrashekar et al., 2017</xref>).</p></sec><sec id="s4-10"><title>Statistical analyses</title><p>All statistical analyses are detailed in the relevant figure legends. In all cases, calculated p values less than or equal to 0.05 were considered significant. <italic>N</italic> numbers for each experiment are detailed within each figure, as individual points on graphs or within figure legends.</p></sec></sec></body><back><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Formal analysis, Investigation, Methodology, Project administration, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Investigation</p></fn><fn fn-type="con" id="con3"><p>Investigation</p></fn><fn fn-type="con" id="con4"><p>Investigation</p></fn><fn fn-type="con" id="con5"><p>Investigation</p></fn><fn fn-type="con" id="con6"><p>Resources</p></fn><fn fn-type="con" id="con7"><p>Conceptualization, Funding acquisition</p></fn><fn fn-type="con" id="con8"><p>Conceptualization, Funding acquisition</p></fn><fn fn-type="con" id="con9"><p>Conceptualization, Funding acquisition</p></fn><fn fn-type="con" id="con10"><p>Conceptualization, Funding acquisition, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con11"><p>Conceptualization, Funding acquisition, Project administration, Supervision, Writing - original draft, Writing - review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Experiments with mice were performed under a licence from the UK Home Office (licence numbers 60/4183 and 70/8646).</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-69729-transrepform1-v1.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>Source data for Figure 1F, Figure 3 - figure supplement 1, Figure 3 - figure supplement 2, Figure 4F and Figure 6 - figure supplement 2 have been uploaded.</p></sec><ack id="ack"><title>Acknowledgements</title><p>The Sansom laboratory was funded by CRUK (A17196, A24388, and A21139), The European Research Council ColonCan (311301). This work was also funded by a Wellcome Trust Collaborative Award in Science (201487) to GM, CMS, TvdH, AEW, and OS. We are grateful to the Advanced Technologies and Core Services at the Beatson Institute (funded by CRUK C596/A17196 and A31287), particularly the Biological Services Unit, Histology Services and Transgenic Technology Laboratory. CGP is supported by funding from the National Health and Medical Research Council (Australia). We thank Daniel Murphy for kindly supplying antibodies for ACC and P-ACC. We thank Fiona Warrander for critical reading of the manuscript.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ballard</surname><given-names>DJ</given-names></name><name><surname>Peng</surname><given-names>HY</given-names></name><name><surname>Das</surname><given-names>JK</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Ren</surname><given-names>Y</given-names></name><name><surname>Xiong</surname><given-names>X</given-names></name><name><surname>Ren</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>JM</given-names></name><name><surname>Song</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Insights Into the Pathologic Roles and Regulation of Eukaryotic Elongation Factor-2 Kinase</article-title><source>Frontiers in Molecular Biosciences</source><volume>8</volume><elocation-id>839</elocation-id><pub-id pub-id-type="doi">10.3389/fmolb.2021.727863</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barkić</surname><given-names>M</given-names></name><name><surname>Crnomarković</surname><given-names>S</given-names></name><name><surname>Grabusić</surname><given-names>K</given-names></name><name><surname>Bogetić</surname><given-names>I</given-names></name><name><surname>Panić</surname><given-names>L</given-names></name><name><surname>Tamarut</surname><given-names>S</given-names></name><name><surname>Cokarić</surname><given-names>M</given-names></name><name><surname>Jerić</surname><given-names>I</given-names></name><name><surname>Vidak</surname><given-names>S</given-names></name><name><surname>Volarević</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The p53 tumor suppressor causes congenital malformations in Rpl24-deficient mice and promotes their survival</article-title><source>Molecular and Cellular Biology</source><volume>29</volume><fpage>2489</fpage><lpage>2504</lpage><pub-id pub-id-type="doi">10.1128/MCB.01588-08</pub-id><pub-id pub-id-type="pmid">19273598</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barna</surname><given-names>M</given-names></name><name><surname>Pusic</surname><given-names>A</given-names></name><name><surname>Zollo</surname><given-names>O</given-names></name><name><surname>Costa</surname><given-names>M</given-names></name><name><surname>Kondrashov</surname><given-names>N</given-names></name><name><surname>Rego</surname><given-names>E</given-names></name><name><surname>Rao</surname><given-names>PH</given-names></name><name><surname>Ruggero</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Suppression of Myc oncogenic activity by ribosomal protein haploinsufficiency</article-title><source>Nature</source><volume>456</volume><fpage>971</fpage><lpage>975</lpage><pub-id pub-id-type="doi">10.1038/nature07449</pub-id><pub-id pub-id-type="pmid">19011615</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartha</surname><given-names>Á</given-names></name><name><surname>Győrffy</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>TNMplot.com: A Web Tool for the Comparison of Gene Expression in Normal, Tumor and Metastatic Tissues</article-title><source>International Journal of Molecular Sciences</source><volume>22</volume><elocation-id>2622</elocation-id><pub-id pub-id-type="doi">10.3390/ijms22052622</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carlberg</surname><given-names>U</given-names></name><name><surname>Nilsson</surname><given-names>A</given-names></name><name><surname>Nygård</surname><given-names>O</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>Functional properties of phosphorylated elongation factor 2</article-title><source>European Journal of Biochemistry</source><volume>191</volume><fpage>639</fpage><lpage>645</lpage><pub-id pub-id-type="doi">10.1111/j.1432-1033.1990.tb19169.x</pub-id><pub-id pub-id-type="pmid">2390990</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cerezo</surname><given-names>M</given-names></name><name><surname>Guemiri</surname><given-names>R</given-names></name><name><surname>Druillennec</surname><given-names>S</given-names></name><name><surname>Girault</surname><given-names>I</given-names></name><name><surname>Malka-Mahieu</surname><given-names>H</given-names></name><name><surname>Shen</surname><given-names>S</given-names></name><name><surname>Allard</surname><given-names>D</given-names></name><name><surname>Martineau</surname><given-names>S</given-names></name><name><surname>Welsch</surname><given-names>C</given-names></name><name><surname>Agoussi</surname><given-names>S</given-names></name><name><surname>Estrada</surname><given-names>C</given-names></name><name><surname>Adam</surname><given-names>J</given-names></name><name><surname>Libenciuc</surname><given-names>C</given-names></name><name><surname>Routier</surname><given-names>E</given-names></name><name><surname>Roy</surname><given-names>S</given-names></name><name><surname>Désaubry</surname><given-names>L</given-names></name><name><surname>Eggermont</surname><given-names>AM</given-names></name><name><surname>Sonenberg</surname><given-names>N</given-names></name><name><surname>Scoazec</surname><given-names>JY</given-names></name><name><surname>Eychène</surname><given-names>A</given-names></name><name><surname>Vagner</surname><given-names>S</given-names></name><name><surname>Robert</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Translational control of tumor immune escape via the eIF4F-STAT1-PD-L1 axis in melanoma</article-title><source>Nature Medicine</source><volume>24</volume><fpage>1877</fpage><lpage>1886</lpage><pub-id pub-id-type="doi">10.1038/s41591-018-0217-1</pub-id><pub-id pub-id-type="pmid">30374200</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chandrashekar</surname><given-names>DS</given-names></name><name><surname>Bashel</surname><given-names>B</given-names></name><name><surname>Balasubramanya</surname><given-names>SAH</given-names></name><name><surname>Creighton</surname><given-names>CJ</given-names></name><name><surname>Ponce-Rodriguez</surname><given-names>I</given-names></name><name><surname>Chakravarthi</surname><given-names>BVSK</given-names></name><name><surname>Varambally</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses</article-title><source>Neoplasia</source><volume>19</volume><fpage>649</fpage><lpage>658</lpage><pub-id pub-id-type="doi">10.1016/j.neo.2017.05.002</pub-id><pub-id pub-id-type="pmid">28732212</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeStefanis</surname><given-names>RA</given-names></name><name><surname>Kratz</surname><given-names>JD</given-names></name><name><surname>Emmerich</surname><given-names>PB</given-names></name><name><surname>Deming</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Targeted Therapy in Metastatic Colorectal Cancer: Current Standards and Novel Agents in Review</article-title><source>Current Colorectal Cancer Reports</source><volume>15</volume><fpage>61</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1007/s11888-019-00430-6</pub-id><pub-id pub-id-type="pmid">31130830</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>el Marjou</surname><given-names>F</given-names></name><name><surname>Janssen</surname><given-names>K-P</given-names></name><name><surname>Chang</surname><given-names>BH-J</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Hindie</surname><given-names>V</given-names></name><name><surname>Chan</surname><given-names>L</given-names></name><name><surname>Louvard</surname><given-names>D</given-names></name><name><surname>Chambon</surname><given-names>P</given-names></name><name><surname>Metzger</surname><given-names>D</given-names></name><name><surname>Robine</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Tissue-specific and inducible Cre-mediated recombination in the gut epithelium</article-title><source>Genesis</source><volume>39</volume><fpage>186</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.1002/gene.20042</pub-id><pub-id pub-id-type="pmid">15282745</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faller</surname><given-names>WJ</given-names></name><name><surname>Jackson</surname><given-names>TJ</given-names></name><name><surname>Knight</surname><given-names>JR</given-names></name><name><surname>Ridgway</surname><given-names>RA</given-names></name><name><surname>Jamieson</surname><given-names>T</given-names></name><name><surname>Karim</surname><given-names>SA</given-names></name><name><surname>Jones</surname><given-names>C</given-names></name><name><surname>Radulescu</surname><given-names>S</given-names></name><name><surname>Huels</surname><given-names>DJ</given-names></name><name><surname>Myant</surname><given-names>KB</given-names></name><name><surname>Dudek</surname><given-names>KM</given-names></name><name><surname>Casey</surname><given-names>HA</given-names></name><name><surname>Scopelliti</surname><given-names>A</given-names></name><name><surname>Cordero</surname><given-names>JB</given-names></name><name><surname>Vidal</surname><given-names>M</given-names></name><name><surname>Pende</surname><given-names>M</given-names></name><name><surname>Ryazanov</surname><given-names>AG</given-names></name><name><surname>Sonenberg</surname><given-names>N</given-names></name><name><surname>Meyuhas</surname><given-names>O</given-names></name><name><surname>Hall</surname><given-names>MN</given-names></name><name><surname>Bushell</surname><given-names>M</given-names></name><name><surname>Willis</surname><given-names>AE</given-names></name><name><surname>Sansom</surname><given-names>OJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>mTORC1-mediated translational elongation limits intestinal tumour initiation and growth</article-title><source>Nature</source><volume>517</volume><fpage>497</fpage><lpage>500</lpage><pub-id pub-id-type="doi">10.1038/nature13896</pub-id><pub-id pub-id-type="pmid">25383520</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faul</surname><given-names>F</given-names></name><name><surname>Erdfelder</surname><given-names>E</given-names></name><name><surname>Buchner</surname><given-names>A</given-names></name><name><surname>Lang</surname><given-names>AG</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses</article-title><source>Behavior Research Methods</source><volume>41</volume><fpage>1149</fpage><lpage>1160</lpage><pub-id pub-id-type="doi">10.3758/BRM.41.4.1149</pub-id><pub-id pub-id-type="pmid">19897823</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gay</surname><given-names>DM</given-names></name><name><surname>Lund</surname><given-names>AH</given-names></name><name><surname>Jansson</surname><given-names>MD</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Translational control through ribosome heterogeneity and functional specialization</article-title><source>Trends in Biochemical Sciences</source><volume>23</volume><elocation-id>00144-4</elocation-id><pub-id pub-id-type="doi">10.1016/j.tibs.2021.07.001</pub-id><pub-id pub-id-type="pmid">34312084</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gildish</surname><given-names>I</given-names></name><name><surname>Manor</surname><given-names>D</given-names></name><name><surname>David</surname><given-names>O</given-names></name><name><surname>Sharma</surname><given-names>V</given-names></name><name><surname>Williams</surname><given-names>D</given-names></name><name><surname>Agarwala</surname><given-names>U</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Kenney</surname><given-names>JW</given-names></name><name><surname>Proud</surname><given-names>CG</given-names></name><name><surname>Rosenblum</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Impaired associative taste learning and abnormal brain activation in kinase-defective eEF2K mice</article-title><source>Learning &amp; Memory</source><volume>19</volume><fpage>116</fpage><lpage>125</lpage><pub-id pub-id-type="doi">10.1101/lm.023937.111</pub-id><pub-id pub-id-type="pmid">22366775</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guinney</surname><given-names>J</given-names></name><name><surname>Dienstmann</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>de Reyniès</surname><given-names>A</given-names></name><name><surname>Schlicker</surname><given-names>A</given-names></name><name><surname>Soneson</surname><given-names>C</given-names></name><name><surname>Marisa</surname><given-names>L</given-names></name><name><surname>Roepman</surname><given-names>P</given-names></name><name><surname>Nyamundanda</surname><given-names>G</given-names></name><name><surname>Angelino</surname><given-names>P</given-names></name><name><surname>Bot</surname><given-names>BM</given-names></name><name><surname>Morris</surname><given-names>JS</given-names></name><name><surname>Simon</surname><given-names>IM</given-names></name><name><surname>Gerster</surname><given-names>S</given-names></name><name><surname>Fessler</surname><given-names>E</given-names></name><name><surname>De Sousa E Melo</surname><given-names>F</given-names></name><name><surname>Missiaglia</surname><given-names>E</given-names></name><name><surname>Ramay</surname><given-names>H</given-names></name><name><surname>Barras</surname><given-names>D</given-names></name><name><surname>Homicsko</surname><given-names>K</given-names></name><name><surname>Maru</surname><given-names>D</given-names></name><name><surname>Manyam</surname><given-names>GC</given-names></name><name><surname>Broom</surname><given-names>B</given-names></name><name><surname>Boige</surname><given-names>V</given-names></name><name><surname>Perez-Villamil</surname><given-names>B</given-names></name><name><surname>Laderas</surname><given-names>T</given-names></name><name><surname>Salazar</surname><given-names>R</given-names></name><name><surname>Gray</surname><given-names>JW</given-names></name><name><surname>Hanahan</surname><given-names>D</given-names></name><name><surname>Tabernero</surname><given-names>J</given-names></name><name><surname>Bernards</surname><given-names>R</given-names></name><name><surname>Friend</surname><given-names>SH</given-names></name><name><surname>Laurent-Puig</surname><given-names>P</given-names></name><name><surname>Medema</surname><given-names>JP</given-names></name><name><surname>Sadanandam</surname><given-names>A</given-names></name><name><surname>Wessels</surname><given-names>L</given-names></name><name><surname>Delorenzi</surname><given-names>M</given-names></name><name><surname>Kopetz</surname><given-names>S</given-names></name><name><surname>Vermeulen</surname><given-names>L</given-names></name><name><surname>Tejpar</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The consensus molecular subtypes of colorectal cancer</article-title><source>Nature Medicine</source><volume>21</volume><fpage>1350</fpage><lpage>1356</lpage><pub-id pub-id-type="doi">10.1038/nm.3967</pub-id><pub-id pub-id-type="pmid">26457759</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herrlinger</surname><given-names>S</given-names></name><name><surname>Shao</surname><given-names>Q</given-names></name><name><surname>Yang</surname><given-names>M</given-names></name><name><surname>Chang</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Pan</surname><given-names>X</given-names></name><name><surname>Yin</surname><given-names>H</given-names></name><name><surname>Xie</surname><given-names>LW</given-names></name><name><surname>Chen</surname><given-names>JF</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Lin28-mediated temporal promotion of protein synthesis is crucial for neural progenitor cell maintenance and brain development in mice</article-title><source>Development</source><volume>146</volume><elocation-id>dev173765</elocation-id><pub-id pub-id-type="doi">10.1242/dev.173765</pub-id><pub-id pub-id-type="pmid">31064784</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>DS</given-names></name><name><surname>Fakih</surname><given-names>MG</given-names></name><name><surname>Strickler</surname><given-names>JH</given-names></name><name><surname>Desai</surname><given-names>J</given-names></name><name><surname>Durm</surname><given-names>GA</given-names></name><name><surname>Shapiro</surname><given-names>GI</given-names></name><name><surname>Falchook</surname><given-names>GS</given-names></name><name><surname>Price</surname><given-names>TJ</given-names></name><name><surname>Sacher</surname><given-names>A</given-names></name><name><surname>Denlinger</surname><given-names>CS</given-names></name><name><surname>Bang</surname><given-names>Y-J</given-names></name><name><surname>Dy</surname><given-names>GK</given-names></name><name><surname>Krauss</surname><given-names>JC</given-names></name><name><surname>Kuboki</surname><given-names>Y</given-names></name><name><surname>Kuo</surname><given-names>JC</given-names></name><name><surname>Coveler</surname><given-names>AL</given-names></name><name><surname>Park</surname><given-names>K</given-names></name><name><surname>Kim</surname><given-names>TW</given-names></name><name><surname>Barlesi</surname><given-names>F</given-names></name><name><surname>Munster</surname><given-names>PN</given-names></name><name><surname>Ramalingam</surname><given-names>SS</given-names></name><name><surname>Burns</surname><given-names>TF</given-names></name><name><surname>Meric-Bernstam</surname><given-names>F</given-names></name><name><surname>Henary</surname><given-names>H</given-names></name><name><surname>Ngang</surname><given-names>J</given-names></name><name><surname>Ngarmchamnanrith</surname><given-names>G</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Houk</surname><given-names>BE</given-names></name><name><surname>Canon</surname><given-names>J</given-names></name><name><surname>Lipford</surname><given-names>JR</given-names></name><name><surname>Friberg</surname><given-names>G</given-names></name><name><surname>Lito</surname><given-names>P</given-names></name><name><surname>Govindan</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>BT</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors</article-title><source>The New England Journal of Medicine</source><volume>383</volume><fpage>1207</fpage><lpage>1217</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1917239</pub-id><pub-id pub-id-type="pmid">32955176</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsieh</surname><given-names>AC</given-names></name><name><surname>Costa</surname><given-names>M</given-names></name><name><surname>Zollo</surname><given-names>O</given-names></name><name><surname>Davis</surname><given-names>C</given-names></name><name><surname>Feldman</surname><given-names>ME</given-names></name><name><surname>Testa</surname><given-names>JR</given-names></name><name><surname>Meyuhas</surname><given-names>O</given-names></name><name><surname>Shokat</surname><given-names>KM</given-names></name><name><surname>Ruggero</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E</article-title><source>Cancer Cell</source><volume>17</volume><fpage>249</fpage><lpage>261</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2010.01.021</pub-id><pub-id pub-id-type="pmid">20227039</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jackson</surname><given-names>EL</given-names></name><name><surname>Willis</surname><given-names>N</given-names></name><name><surname>Mercer</surname><given-names>K</given-names></name><name><surname>Bronson</surname><given-names>RT</given-names></name><name><surname>Crowley</surname><given-names>D</given-names></name><name><surname>Montoya</surname><given-names>R</given-names></name><name><surname>Jacks</surname><given-names>T</given-names></name><name><surname>Tuveson</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras</article-title><source>Genes &amp; Development</source><volume>15</volume><fpage>3243</fpage><lpage>3248</lpage><pub-id pub-id-type="doi">10.1101/gad.943001</pub-id><pub-id pub-id-type="pmid">11751630</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jana</surname><given-names>S</given-names></name><name><surname>Deo</surname><given-names>R</given-names></name><name><surname>Hough</surname><given-names>RP</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Horn</surname><given-names>JL</given-names></name><name><surname>Wright</surname><given-names>JL</given-names></name><name><surname>Lam</surname><given-names>H-M</given-names></name><name><surname>Webster</surname><given-names>KR</given-names></name><name><surname>Chiang</surname><given-names>GG</given-names></name><name><surname>Sonenberg</surname><given-names>N</given-names></name><name><surname>Hsieh</surname><given-names>AC</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>mRNA translation is a therapeutic vulnerability necessary for bladder epithelial transformation</article-title><source>JCI Insight</source><volume>6</volume><elocation-id>e144920</elocation-id><pub-id pub-id-type="doi">10.1172/jci.insight.144920</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keysar</surname><given-names>SB</given-names></name><name><surname>Gomes</surname><given-names>N</given-names></name><name><surname>Miller</surname><given-names>B</given-names></name><name><surname>Jackson</surname><given-names>BC</given-names></name><name><surname>Le</surname><given-names>PN</given-names></name><name><surname>Morton</surname><given-names>JJ</given-names></name><name><surname>Reisinger</surname><given-names>J</given-names></name><name><surname>Chimed</surname><given-names>T-S</given-names></name><name><surname>Gomez</surname><given-names>KE</given-names></name><name><surname>Nieto</surname><given-names>C</given-names></name><name><surname>Frederick</surname><given-names>B</given-names></name><name><surname>Pronk</surname><given-names>GJ</given-names></name><name><surname>Somerset</surname><given-names>HL</given-names></name><name><surname>Tan</surname><given-names>A-C</given-names></name><name><surname>Wang</surname><given-names>X-J</given-names></name><name><surname>Raben</surname><given-names>D</given-names></name><name><surname>Su</surname><given-names>TT</given-names></name><name><surname>Jimeno</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Inhibiting Translation Elongation with SVC112 Suppresses Cancer Stem Cells and Inhibits Growth in Head and Neck Squamous Carcinoma</article-title><source>Cancer Research</source><volume>80</volume><fpage>1183</fpage><lpage>1198</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-19-3232</pub-id><pub-id pub-id-type="pmid">31911553</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knight</surname><given-names>JRP</given-names></name><name><surname>Willis</surname><given-names>AE</given-names></name><name><surname>Milner</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Active regulator of SIRT1 is required for ribosome biogenesis and function</article-title><source>Nucleic Acids Research</source><volume>41</volume><fpage>4185</fpage><lpage>4197</lpage><pub-id pub-id-type="doi">10.1093/nar/gkt129</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knight</surname><given-names>JRP</given-names></name><name><surname>Bastide</surname><given-names>A</given-names></name><name><surname>Roobol</surname><given-names>A</given-names></name><name><surname>Roobol</surname><given-names>J</given-names></name><name><surname>Jackson</surname><given-names>TJ</given-names></name><name><surname>Utami</surname><given-names>W</given-names></name><name><surname>Barrett</surname><given-names>DA</given-names></name><name><surname>Smales</surname><given-names>CM</given-names></name><name><surname>Willis</surname><given-names>AE</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Eukaryotic elongation factor 2 kinase regulates the cold stress response by slowing translation elongation</article-title><source>The Biochemical Journal</source><volume>465</volume><fpage>227</fpage><lpage>238</lpage><pub-id pub-id-type="doi">10.1042/BJ20141014</pub-id><pub-id pub-id-type="pmid">25353634</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knight</surname><given-names>JRP</given-names></name><name><surname>Alexandrou</surname><given-names>C</given-names></name><name><surname>Skalka</surname><given-names>GL</given-names></name><name><surname>Vlahov</surname><given-names>N</given-names></name><name><surname>Pennel</surname><given-names>K</given-names></name><name><surname>Officer</surname><given-names>L</given-names></name><name><surname>Teodosio</surname><given-names>A</given-names></name><name><surname>Kanellos</surname><given-names>G</given-names></name><name><surname>Gay</surname><given-names>DM</given-names></name><name><surname>May-Wilson</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020a</year><article-title>MNK inhibition sensitizes KRAS-mutant colorectal cancer to mTORC1 inhibition by reducing eIF4E phosphorylation and c-MYC expression</article-title><source>Cancer Discovery</source><volume>20</volume><elocation-id>0652</elocation-id><pub-id pub-id-type="doi">10.1158/2159-8290.CD-20-0652</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knight</surname><given-names>JRP</given-names></name><name><surname>Garland</surname><given-names>G</given-names></name><name><surname>Pöyry</surname><given-names>T</given-names></name><name><surname>Mead</surname><given-names>E</given-names></name><name><surname>Vlahov</surname><given-names>N</given-names></name><name><surname>Sfakianos</surname><given-names>A</given-names></name><name><surname>Grosso</surname><given-names>S</given-names></name><name><surname>De-Lima-Hedayioglu</surname><given-names>F</given-names></name><name><surname>Mallucci</surname><given-names>GR</given-names></name><name><surname>von der Haar</surname><given-names>T</given-names></name><name><surname>Smales</surname><given-names>CM</given-names></name><name><surname>Sansom</surname><given-names>OJ</given-names></name><name><surname>Willis</surname><given-names>AE</given-names></name></person-group><year iso-8601-date="2020">2020b</year><article-title>Control of translation elongation in health and disease</article-title><source>Disease Models &amp; Mechanisms</source><volume>13</volume><elocation-id>dmm043208</elocation-id><pub-id pub-id-type="doi">10.1242/dmm.043208</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knight</surname><given-names>JRP</given-names></name><name><surname>Sansom</surname><given-names>OJ</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Tuning protein synthesis for cancer therapy</article-title><source>Molecular &amp; Cellular Oncology</source><volume>8</volume><elocation-id>1884034</elocation-id><pub-id pub-id-type="doi">10.1080/23723556.2021.1884034</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leprivier</surname><given-names>G</given-names></name><name><surname>Remke</surname><given-names>M</given-names></name><name><surname>Rotblat</surname><given-names>B</given-names></name><name><surname>Dubuc</surname><given-names>A</given-names></name><name><surname>Mateo</surname><given-names>A-RF</given-names></name><name><surname>Kool</surname><given-names>M</given-names></name><name><surname>Agnihotri</surname><given-names>S</given-names></name><name><surname>El-Naggar</surname><given-names>A</given-names></name><name><surname>Yu</surname><given-names>B</given-names></name><name><surname>Somasekharan</surname><given-names>SP</given-names></name><name><surname>Faubert</surname><given-names>B</given-names></name><name><surname>Bridon</surname><given-names>G</given-names></name><name><surname>Tognon</surname><given-names>CE</given-names></name><name><surname>Mathers</surname><given-names>J</given-names></name><name><surname>Thomas</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>A</given-names></name><name><surname>Barokas</surname><given-names>A</given-names></name><name><surname>Kwok</surname><given-names>B</given-names></name><name><surname>Bowden</surname><given-names>M</given-names></name><name><surname>Smith</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Korshunov</surname><given-names>A</given-names></name><name><surname>Hielscher</surname><given-names>T</given-names></name><name><surname>Northcott</surname><given-names>PA</given-names></name><name><surname>Galpin</surname><given-names>JD</given-names></name><name><surname>Ahern</surname><given-names>CA</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>McCabe</surname><given-names>MG</given-names></name><name><surname>Collins</surname><given-names>VP</given-names></name><name><surname>Jones</surname><given-names>RG</given-names></name><name><surname>Pollak</surname><given-names>M</given-names></name><name><surname>Delattre</surname><given-names>O</given-names></name><name><surname>Gleave</surname><given-names>ME</given-names></name><name><surname>Jan</surname><given-names>E</given-names></name><name><surname>Pfister</surname><given-names>SM</given-names></name><name><surname>Proud</surname><given-names>CG</given-names></name><name><surname>Derry</surname><given-names>WB</given-names></name><name><surname>Taylor</surname><given-names>MD</given-names></name><name><surname>Sorensen</surname><given-names>PH</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The eEF2 kinase confers resistance to nutrient deprivation by blocking translation elongation</article-title><source>Cell</source><volume>153</volume><fpage>1064</fpage><lpage>1079</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2013.04.055</pub-id><pub-id pub-id-type="pmid">23706743</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moser</surname><given-names>AR</given-names></name><name><surname>Pitot</surname><given-names>HC</given-names></name><name><surname>Dove</surname><given-names>WF</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse</article-title><source>Science</source><volume>247</volume><fpage>322</fpage><lpage>324</lpage><pub-id pub-id-type="doi">10.1126/science.2296722</pub-id><pub-id pub-id-type="pmid">2296722</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Najumudeen</surname><given-names>AK</given-names></name><name><surname>Ceteci</surname><given-names>F</given-names></name><name><surname>Fey</surname><given-names>SK</given-names></name><name><surname>Hamm</surname><given-names>G</given-names></name><name><surname>Steven</surname><given-names>RT</given-names></name><name><surname>Hall</surname><given-names>H</given-names></name><name><surname>Nikula</surname><given-names>CJ</given-names></name><name><surname>Dexter</surname><given-names>A</given-names></name><name><surname>Murta</surname><given-names>T</given-names></name><name><surname>Race</surname><given-names>AM</given-names></name><name><surname>Sumpton</surname><given-names>D</given-names></name><name><surname>Vlahov</surname><given-names>N</given-names></name><name><surname>Gay</surname><given-names>DM</given-names></name><name><surname>Knight</surname><given-names>JRP</given-names></name><name><surname>Jackstadt</surname><given-names>R</given-names></name><name><surname>Leach</surname><given-names>JDG</given-names></name><name><surname>Ridgway</surname><given-names>RA</given-names></name><name><surname>Johnson</surname><given-names>ER</given-names></name><name><surname>Nixon</surname><given-names>C</given-names></name><name><surname>Hedley</surname><given-names>A</given-names></name><name><surname>Gilroy</surname><given-names>K</given-names></name><name><surname>Clark</surname><given-names>W</given-names></name><name><surname>Malla</surname><given-names>SB</given-names></name><name><surname>Dunne</surname><given-names>PD</given-names></name><name><surname>Rodriguez-Blanco</surname><given-names>G</given-names></name><name><surname>Critchlow</surname><given-names>SE</given-names></name><name><surname>Mrowinska</surname><given-names>A</given-names></name><name><surname>Malviya</surname><given-names>G</given-names></name><name><surname>Solovyev</surname><given-names>D</given-names></name><name><surname>Brown</surname><given-names>G</given-names></name><name><surname>Lewis</surname><given-names>DY</given-names></name><name><surname>Mackay</surname><given-names>GM</given-names></name><name><surname>Strathdee</surname><given-names>D</given-names></name><name><surname>Tardito</surname><given-names>S</given-names></name><name><surname>Gottlieb</surname><given-names>E</given-names></name><name><surname>Takats</surname><given-names>Z</given-names></name><name><surname>Barry</surname><given-names>ST</given-names></name><name><surname>Goodwin</surname><given-names>RJA</given-names></name><name><surname>Bunch</surname><given-names>J</given-names></name><name><surname>Bushell</surname><given-names>M</given-names></name><name><surname>Campbell</surname><given-names>AD</given-names></name><name><surname>Sansom</surname><given-names>OJ</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The amino acid transporter SLC7A5 is required for efficient growth of KRAS-mutant colorectal cancer</article-title><source>Nature Genetics</source><volume>53</volume><fpage>16</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1038/s41588-020-00753-3</pub-id><pub-id pub-id-type="pmid">33414552</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ng</surname><given-names>K</given-names></name><name><surname>Tabernero</surname><given-names>J</given-names></name><name><surname>Hwang</surname><given-names>J</given-names></name><name><surname>Bajetta</surname><given-names>E</given-names></name><name><surname>Sharma</surname><given-names>S</given-names></name><name><surname>Del Prete</surname><given-names>SA</given-names></name><name><surname>Arrowsmith</surname><given-names>ER</given-names></name><name><surname>Ryan</surname><given-names>DP</given-names></name><name><surname>Sedova</surname><given-names>M</given-names></name><name><surname>Jin</surname><given-names>J</given-names></name><name><surname>Malek</surname><given-names>K</given-names></name><name><surname>Fuchs</surname><given-names>CS</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Phase II study of everolimus in patients with metastatic colorectal adenocarcinoma previously treated with bevacizumab-, fluoropyrimidine-, oxaliplatin-, and irinotecan-based regimens</article-title><source>Clinical Cancer Research</source><volume>19</volume><fpage>3987</fpage><lpage>3995</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-13-0027</pub-id><pub-id pub-id-type="pmid">23743569</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ng</surname><given-names>TH</given-names></name><name><surname>Sham</surname><given-names>KWY</given-names></name><name><surname>Xie</surname><given-names>CM</given-names></name><name><surname>Ng</surname><given-names>SSM</given-names></name><name><surname>To</surname><given-names>KF</given-names></name><name><surname>Tong</surname><given-names>JHM</given-names></name><name><surname>Liu</surname><given-names>WYZ</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Chan</surname><given-names>MTV</given-names></name><name><surname>Wu</surname><given-names>WKK</given-names></name><name><surname>Cheng</surname><given-names>CHK</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Eukaryotic elongation factor-2 kinase expression is an independent prognostic factor in colorectal cancer</article-title><source>BMC Cancer</source><volume>19</volume><elocation-id>649</elocation-id><pub-id pub-id-type="doi">10.1186/s12885-019-5873-0</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oliver</surname><given-names>ER</given-names></name><name><surname>Saunders</surname><given-names>TL</given-names></name><name><surname>Tarlé</surname><given-names>SA</given-names></name><name><surname>Glaser</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Ribosomal protein L24 defect in belly spot and tail (Bst), a mouse Minute</article-title><source>Development</source><volume>131</volume><fpage>3907</fpage><lpage>3920</lpage><pub-id pub-id-type="doi">10.1242/dev.01268</pub-id><pub-id pub-id-type="pmid">15289434</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Proud</surname><given-names>CG</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Phosphorylation and Signal Transduction Pathways in Translational Control</article-title><source>Cold Spring Harbor Perspectives in Biology</source><volume>11</volume><elocation-id>a033050</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a033050</pub-id><pub-id pub-id-type="pmid">29959191</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riazifar</surname><given-names>H</given-names></name><name><surname>Sun</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Rupp</surname><given-names>A</given-names></name><name><surname>Vemaraju</surname><given-names>S</given-names></name><name><surname>Ross-Cisneros</surname><given-names>FN</given-names></name><name><surname>Lang</surname><given-names>RA</given-names></name><name><surname>Sadun</surname><given-names>AA</given-names></name><name><surname>Hattar</surname><given-names>S</given-names></name><name><surname>Guan</surname><given-names>M-X</given-names></name><name><surname>Huang</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Phenotypic and functional characterization of Bst+/- mouse retina</article-title><source>Disease Models &amp; Mechanisms</source><volume>8</volume><fpage>969</fpage><lpage>976</lpage><pub-id pub-id-type="doi">10.1242/dmm.018176</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robichaud</surname><given-names>N</given-names></name><name><surname>Sonenberg</surname><given-names>N</given-names></name><name><surname>Ruggero</surname><given-names>D</given-names></name><name><surname>Schneider</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Translational Control in Cancer</article-title><source>Cold Spring Harbor Perspectives in Biology</source><volume>11</volume><elocation-id>a032896</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a032896</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roos</surname><given-names>VH</given-names></name><name><surname>Meijer</surname><given-names>BJ</given-names></name><name><surname>Kallenberg</surname><given-names>FGJ</given-names></name><name><surname>Bastiaansen</surname><given-names>BAJ</given-names></name><name><surname>Koens</surname><given-names>L</given-names></name><name><surname>Bemelman</surname><given-names>FJ</given-names></name><name><surname>Bossuyt</surname><given-names>PMM</given-names></name><name><surname>Heijmans</surname><given-names>J</given-names></name><name><surname>van den Brink</surname><given-names>G</given-names></name><name><surname>Dekker</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Sirolimus for the treatment of polyposis of the rectal remnant and ileal pouch in four patients with familial adenomatous polyposis: a pilot study</article-title><source>BMJ Open Gastroenterology</source><volume>7</volume><elocation-id>e000497</elocation-id><pub-id pub-id-type="doi">10.1136/bmjgast-2020-000497</pub-id><pub-id pub-id-type="pmid">33376109</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rueden</surname><given-names>CT</given-names></name><name><surname>Schindelin</surname><given-names>J</given-names></name><name><surname>Hiner</surname><given-names>MC</given-names></name><name><surname>DeZonia</surname><given-names>BE</given-names></name><name><surname>Walter</surname><given-names>AE</given-names></name><name><surname>Arena</surname><given-names>ET</given-names></name><name><surname>Eliceiri</surname><given-names>KW</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>ImageJ2: ImageJ for the next generation of scientific image data</article-title><source>BMC Bioinformatics</source><volume>18</volume><elocation-id>529</elocation-id><pub-id pub-id-type="doi">10.1186/s12859-017-1934-z</pub-id><pub-id pub-id-type="pmid">29187165</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryazanov</surname><given-names>AG</given-names></name><name><surname>Davydova</surname><given-names>EK</given-names></name></person-group><year iso-8601-date="1989">1989</year><article-title>Mechanism of elongation factor 2 (EF-2) inactivation upon phosphorylation: Phosphorylated EF-2 is unable to catalyze translocation</article-title><source>FEBS Letters</source><volume>251</volume><fpage>187</fpage><lpage>190</lpage><pub-id pub-id-type="doi">10.1016/0014-5793(89)81452-8</pub-id><pub-id pub-id-type="pmid">2753158</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saveanu</surname><given-names>C</given-names></name><name><surname>Namane</surname><given-names>A</given-names></name><name><surname>Gleizes</surname><given-names>PE</given-names></name><name><surname>Lebreton</surname><given-names>A</given-names></name><name><surname>Rousselle</surname><given-names>JC</given-names></name><name><surname>Noaillac-Depeyre</surname><given-names>J</given-names></name><name><surname>Gas</surname><given-names>N</given-names></name><name><surname>Jacquier</surname><given-names>A</given-names></name><name><surname>Fromont-Racine</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Sequential Protein Association with Nascent 60S Ribosomal Particles</article-title><source>Molecular and Cellular Biology</source><volume>23</volume><fpage>4449</fpage><lpage>4460</lpage><pub-id pub-id-type="doi">10.1128/MCB.23.13.4449-4460.2003</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shibata</surname><given-names>H</given-names></name><name><surname>Toyama</surname><given-names>K</given-names></name><name><surname>Shioya</surname><given-names>H</given-names></name><name><surname>Ito</surname><given-names>M</given-names></name><name><surname>Hirota</surname><given-names>M</given-names></name><name><surname>Hasegawa</surname><given-names>S</given-names></name><name><surname>Matsumoto</surname><given-names>H</given-names></name><name><surname>Takano</surname><given-names>H</given-names></name><name><surname>Akiyama</surname><given-names>T</given-names></name><name><surname>Toyoshima</surname><given-names>K</given-names></name><name><surname>Kanamaru</surname><given-names>R</given-names></name><name><surname>Kanegae</surname><given-names>Y</given-names></name><name><surname>Saito</surname><given-names>I</given-names></name><name><surname>Nakamura</surname><given-names>Y</given-names></name><name><surname>Shiba</surname><given-names>K</given-names></name><name><surname>Noda</surname><given-names>T</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Rapid colorectal adenoma formation initiated by conditional targeting of the Apc gene</article-title><source>Science</source><volume>278</volume><fpage>120</fpage><lpage>123</lpage><pub-id pub-id-type="doi">10.1126/science.278.5335.120</pub-id><pub-id pub-id-type="pmid">9311916</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Signer</surname><given-names>RAJ</given-names></name><name><surname>Magee</surname><given-names>JA</given-names></name><name><surname>Salic</surname><given-names>A</given-names></name><name><surname>Morrison</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Haematopoietic stem cells require a highly regulated protein synthesis rate</article-title><source>Nature</source><volume>509</volume><fpage>49</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1038/nature13035</pub-id><pub-id pub-id-type="pmid">24670665</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smit</surname><given-names>WL</given-names></name><name><surname>Spaan</surname><given-names>CN</given-names></name><name><surname>Johannes de Boer</surname><given-names>R</given-names></name><name><surname>Ramesh</surname><given-names>P</given-names></name><name><surname>Martins Garcia</surname><given-names>T</given-names></name><name><surname>Meijer</surname><given-names>BJ</given-names></name><name><surname>Vermeulen</surname><given-names>JLM</given-names></name><name><surname>Lezzerini</surname><given-names>M</given-names></name><name><surname>MacInnes</surname><given-names>AW</given-names></name><name><surname>Koster</surname><given-names>J</given-names></name><name><surname>Medema</surname><given-names>JP</given-names></name><name><surname>van den Brink</surname><given-names>GR</given-names></name><name><surname>Muncan</surname><given-names>V</given-names></name><name><surname>Heijmans</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Driver mutations of the adenoma-carcinoma sequence govern the intestinal epithelial global translational capacity</article-title><source>PNAS</source><volume>117</volume><fpage>25560</fpage><lpage>25570</lpage><pub-id pub-id-type="doi">10.1073/pnas.1912772117</pub-id><pub-id pub-id-type="pmid">32989144</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>RCL</given-names></name><name><surname>Kanellos</surname><given-names>G</given-names></name><name><surname>Vlahov</surname><given-names>N</given-names></name><name><surname>Alexandrou</surname><given-names>C</given-names></name><name><surname>Willis</surname><given-names>AE</given-names></name><name><surname>Knight</surname><given-names>JRP</given-names></name><name><surname>Sansom</surname><given-names>OJ</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Translation initiation in cancer at a glance</article-title><source>Journal of Cell Science</source><volume>134</volume><elocation-id>jcs248476</elocation-id><pub-id pub-id-type="doi">10.1242/jcs.248476</pub-id><pub-id pub-id-type="pmid">33441326</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spindler</surname><given-names>KLG</given-names></name><name><surname>Sorensen</surname><given-names>MM</given-names></name><name><surname>Pallisgaard</surname><given-names>N</given-names></name><name><surname>Andersen</surname><given-names>RF</given-names></name><name><surname>Havelund</surname><given-names>BM</given-names></name><name><surname>Ploen</surname><given-names>J</given-names></name><name><surname>Lassen</surname><given-names>U</given-names></name><name><surname>Jakobsen</surname><given-names>AKM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Phase II trial of temsirolimus alone and in combination with irinotecan for KRAS mutant metastatic colorectal cancer: outcome and results of KRAS mutational analysis in plasma</article-title><source>Acta Oncologica</source><volume>52</volume><fpage>963</fpage><lpage>970</lpage><pub-id pub-id-type="doi">10.3109/0284186X.2013.776175</pub-id><pub-id pub-id-type="pmid">23514584</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stickel</surname><given-names>SA</given-names></name><name><surname>Gomes</surname><given-names>NP</given-names></name><name><surname>Frederick</surname><given-names>B</given-names></name><name><surname>Raben</surname><given-names>D</given-names></name><name><surname>Su</surname><given-names>TT</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Bouvardin is a Radiation Modulator with a Novel Mechanism of Action</article-title><source>Radiation Research</source><volume>184</volume><fpage>392</fpage><lpage>403</lpage><pub-id pub-id-type="doi">10.1667/RR14068.1</pub-id><pub-id pub-id-type="pmid">26414509</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suresh</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>B</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Golden</surname><given-names>RJ</given-names></name><name><surname>Lu</surname><given-names>C</given-names></name><name><surname>Evers</surname><given-names>BM</given-names></name><name><surname>Novaresi</surname><given-names>N</given-names></name><name><surname>Smith</surname><given-names>B</given-names></name><name><surname>Zhan</surname><given-names>X</given-names></name><name><surname>Schmid</surname><given-names>V</given-names></name><name><surname>Jun</surname><given-names>S</given-names></name><name><surname>Karacz</surname><given-names>CM</given-names></name><name><surname>Peyton</surname><given-names>M</given-names></name><name><surname>Zhong</surname><given-names>L</given-names></name><name><surname>Wen</surname><given-names>Z</given-names></name><name><surname>Sathe</surname><given-names>AA</given-names></name><name><surname>Xing</surname><given-names>C</given-names></name><name><surname>Behrens</surname><given-names>C</given-names></name><name><surname>Wistuba</surname><given-names>II</given-names></name><name><surname>Xiao</surname><given-names>G</given-names></name><name><surname>Xie</surname><given-names>Y</given-names></name><name><surname>Fu</surname><given-names>YX</given-names></name><name><surname>Minna</surname><given-names>JD</given-names></name><name><surname>Mendell</surname><given-names>JT</given-names></name><name><surname>O’Donnell</surname><given-names>KA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>EIF5B drives integrated stress response-dependent translation of PD-L1 in lung cancer</article-title><source>Nature Cancer</source><volume>1</volume><fpage>533</fpage><lpage>545</lpage><pub-id pub-id-type="doi">10.1038/s43018-020-0056-0</pub-id><pub-id pub-id-type="pmid">32984844</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson-Edell</surname><given-names>KA</given-names></name><name><surname>Kehasse</surname><given-names>A</given-names></name><name><surname>Scott</surname><given-names>GK</given-names></name><name><surname>Yau</surname><given-names>C</given-names></name><name><surname>Rothschild</surname><given-names>DE</given-names></name><name><surname>Schilling</surname><given-names>B</given-names></name><name><surname>Gabriel</surname><given-names>BS</given-names></name><name><surname>Yevtushenko</surname><given-names>MA</given-names></name><name><surname>Hanson</surname><given-names>IM</given-names></name><name><surname>Held</surname><given-names>JM</given-names></name><name><surname>Gibson</surname><given-names>BW</given-names></name><name><surname>Benz</surname><given-names>CC</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>RPL24: a potential therapeutic target whose depletion or acetylation inhibits polysome assembly and cancer cell growth</article-title><source>Oncotarget</source><volume>5</volume><fpage>5165</fpage><lpage>5176</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.2099</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Poggio</surname><given-names>M</given-names></name><name><surname>Jin</surname><given-names>HY</given-names></name><name><surname>Shi</surname><given-names>Z</given-names></name><name><surname>Forester</surname><given-names>CM</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Stumpf</surname><given-names>CR</given-names></name><name><surname>Xue</surname><given-names>L</given-names></name><name><surname>Devericks</surname><given-names>E</given-names></name><name><surname>So</surname><given-names>L</given-names></name><name><surname>Nguyen</surname><given-names>HG</given-names></name><name><surname>Griselin</surname><given-names>A</given-names></name><name><surname>Gordan</surname><given-names>JD</given-names></name><name><surname>Umetsu</surname><given-names>SE</given-names></name><name><surname>Reich</surname><given-names>SH</given-names></name><name><surname>Worland</surname><given-names>ST</given-names></name><name><surname>Asthana</surname><given-names>S</given-names></name><name><surname>Barna</surname><given-names>M</given-names></name><name><surname>Webster</surname><given-names>KR</given-names></name><name><surname>Cunningham</surname><given-names>JT</given-names></name><name><surname>Ruggero</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Translation control of the immune checkpoint in cancer and its therapeutic targeting</article-title><source>Nature Medicine</source><volume>25</volume><fpage>301</fpage><lpage>311</lpage><pub-id pub-id-type="doi">10.1038/s41591-018-0321-2</pub-id><pub-id pub-id-type="pmid">30643286</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuksekkaya</surname><given-names>H</given-names></name><name><surname>Yucel</surname><given-names>A</given-names></name><name><surname>Gumus</surname><given-names>M</given-names></name><name><surname>Esen</surname><given-names>H</given-names></name><name><surname>Toy</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Familial Adenomatous Polyposis; Succesful Use of Sirolimus</article-title><source>The American Journal of Gastroenterology</source><volume>111</volume><fpage>1040</fpage><lpage>1041</lpage><pub-id pub-id-type="doi">10.1038/ajg.2016.159</pub-id><pub-id pub-id-type="pmid">27356835</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.69729.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Frame</surname><given-names>Margaret C</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>University of Edinburgh</institution><country>United Kingdom</country></aff></contrib></contrib-group><related-object id="sa0ro1" link-type="continued-by" object-id="10.1101/2021.05.05.442715" object-id-type="id" xlink:href="https://sciety.org/articles/activity/10.1101/2021.05.05.442715"/></front-stub><body><p>Briefly, Knight and colleagues investigate the role of the ribosome and translational control in colorectal tumours. A mutation of a protein of the large ribosomal subunit, RPL24, is used to suppress tumours driven by two mutations found commonly in cancer, in APC and KRAS. The authors identify a mechanistic output of the RPL24 BST mutation, eEF2 phosphorylation, which they demonstrate is a major effector in inhibiting tumour cell translation and proliferation. By targeting the eEF2 kinase eEF2K, they restore protein synthesis in RPL24 mutant cells. The conclusion is well supported by the experimental data presented, which implies that translation elongation can be a potential therapeutic target of KRAS mutated CRC. Importantly, Rpl24Bst in wildtype intestine does not affect epithelial cell proliferation and differentiation, suggesting that translation elongation can be used as tumour-specific target.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.69729.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Frame</surname><given-names>Margaret C</given-names></name><role>Reviewing Editor</role><aff><institution>University of Edinburgh</institution><country>United Kingdom</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Li</surname><given-names>Vivian SW</given-names></name><role>Reviewer</role><aff><institution>National Institute for Medical Research</institution><country>United Kingdom</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2021.05.05.442715">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2021.05.05.442715v1.full">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Rpl24Bst mutation suppresses colorectal cancer by promoting eEF2 phosphorylation via eEF2K&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 2 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and David Ron as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Vivian Li (Reviewer #1).</p><p>The Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>The manuscript is well written with a strength being the design of experiments that combines genetically modified mouse models, organoid culture, biochemical assays, and transcriptomic analysis to address the role of RPL24 in CRC. The approach is thorough and comprehensive, and there is sufficient evidence provided to support the main conclusions. The only limitations of the work that the authors may wish to address are:</p><p>i) It remains unclear why and how the tumour suppressive role of Rpl24Bst is specific to KRAS G12D mutation only, considering that increased eEF2 phosphorylation is also observed in the KRAS wildtype model, and</p><p>ii) The mechanism by which RPL24-bst induces eEF2-phosphorylation. How direct is this and does it involve ribosome heterogeneity and/or translational stress?</p><p>Importantly this work enhances the concept of targeting translational control in tumours.</p><p>Essential revisions:</p><p>1. The authors provide convincing data showing that Rpl24Bst inhibits CRC proliferation and tumour growth by suppressing protein translation elongation via Eef2k-dependent eEF2 phosphorylation. They further show that the tumour suppressive role of Rpl24Bst is specific to Kras G12D mutation but not in Kras wildtype Apc-deficient animals. The Kras mutant specificity of Rpl24Bst model is very interesting, yet the underlying mechanism is largely unclear. Although we appreciate that the underlying full mechanism might be the scope of another story, it would be helpful if the authors were to elaborate on this point, taking into account the following considerations: In p.260-262, the authors suggest that Rpl24 expression might be sufficient for Apc-deleted models but not Kras mutation due to the limited upregulation of Rpl24 in Figure 4F. However, upregulation of eEF2 phosphorylation in the Apc-deleted models (Figure 4B) is apparently equivalent to the Kras mutant model (Figure S2A). Importantly, the authors show that abrogation of eEF2 phosphorylation via Eef2k inhibition has no effect on tumour growth in Apc-deleted only model (Figure S5B). Alternative explanation of Kras mutation specificity could be that eEF2 phosphorylation (and reduced translation elongation) is only required in Kras mutant tumours but not in Apc-deficient tumours. It will strengthen the hypothesis if the authors can evaluate whether translation elongation is affected in the Eef2k mutant and Apc-deficient tumours to see if translation elongation via Eef2k-p-eEF2-axis is important for Apc mutation.</p><p>2. The BrdU cell counting throughout the manuscript is normalised &quot;per half crypt&quot;. BrdU positive staining often goes beyond the crypts towards villi in Apc mutant and Apc/Kras mutant models. It is unclear how half crypt is defined in hyperproliferative crypts (such as Figure 2C) between genotypes.</p><p>3. In Figure 4B, the BrdU staining is clearly reduced in Apcfl/flRpl24Bst/+ compared to Apcfl/fl intestine, yet quantitation shows no difference. Again, this may depend on how &quot;BrdU<sup>+</sup> cells per half crypt&quot; is defined in different genotypes when there is massive crypt expansion in one but not the other.</p><p>4. In figure S1F, the authors show that mutated Rpl24 restricts irradiation-induced regeneration by quantifying regenerative crypts. How did the authors define &quot;regenerative crypt&quot; without staining? Also, how was the data normalised with all wildtype controls set at = 1?</p><p>5. The authors show that tumour numbers are not affected in Figure S2D and S5E. What about tumour size?</p><p>6. There are multiple figure citation errors in the manuscripts, particularly in result session including line 148-9/figure 1D, lines 243,244/figure4D, line 274/figureS2A, line 277/figure4D, line 279/figure4E and line 287/figureS4E. Please proofread.</p><p>7. The authors claim that there are 75% increase in P-eEF2 and 50% reduction in RPL24 expression in Figure 1F. Where's the quantitation?</p><p>8. Please provide p-value for Figure 4B (H-score of Rpl24 and p-eEF2) and Figure S6B.</p><p>9. Questions remain around the mechanism of action of RPL24-bst. Does RPL24-bst really not alter ribosome abundance? How are the polysome profiles normalised? Are cell equivalents loaded? Could the ratio of different poly fractions be maintained +/- RPL24-bst but total number of ribosomes be reduced?</p><p>10. What is the protein expression level of other RPLs when RPL24bst is expressed? This information for a few RPLs would either support the concept that ribosome number is maintained or would reveal a co-ordinated reduction in large ribosome subunit proteins.</p><p>11. Does reduced RPL24 expression lead to ribosome heterogeneity? If ribosome number is unaltered, but one subunit, RPL24, is reduced, presumably there is ribosome heterogeneity? Would this lead to translational stress?</p><p>12. What is the mechanistic link between RPL24 and eEF2? Any hints at how eEF2 phosphorylation is influenced by RPL24? How direct is the mechanism? Is translational stress involved?</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.69729.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1. The authors provide convincing data showing that Rpl24Bst inhibits CRC proliferation and tumour growth by suppressing protein translation elongation via Eef2k-dependent eEF2 phosphorylation. They further show that the tumour suppressive role of Rpl24Bst is specific to Kras G12D mutation but not in Kras wildtype Apc-deficient animals. The Kras mutant specificity of Rpl24Bst model is very interesting, yet the underlying mechanism is largely unclear. Although we appreciate that the underlying full mechanism might be the scope of another story, it would be helpful if the authors were to elaborate on this point, taking into account the following considerations: In p.260-262, the authors suggest that Rpl24 expression might be sufficient for Apc-deleted models but not Kras mutation due to the limited upregulation of Rpl24 in Figure 4F. However, upregulation of eEF2 phosphorylation in the Apc-deleted models (Figure 4B) is apparently equivalent to the Kras mutant model (Figure S2A). Importantly, the authors show that abrogation of eEF2 phosphorylation via Eef2k inhibition has no effect on tumour growth in Apc-deleted only model (Figure S5B). Alternative explanation of Kras mutation specificity could be that eEF2 phosphorylation (and reduced translation elongation) is only required in Kras mutant tumours but not in Apc-deficient tumours. It will strengthen the hypothesis if the authors can evaluate whether translation elongation is affected in the Eef2k mutant and Apc-deficient tumours to see if translation elongation via Eef2k-p-eEF2-axis is important for Apc mutation.</p></disp-quote><p>We previously published on the importance of translation elongation in <italic>Apc</italic>-deficient mouse models of colorectal cancer, finding that rapamycin suppresses tumorigenesis in a mechanism entirely dependent upon eEF2K expression and signalling to P-eEF2 (Faller et al., Nature, 2015. PMID: 25383520). This is discussed in the introduction (lines 51-58), and again as we introduce the <italic>Apc</italic>-deficient models in the Results section (lines 257-260). Therefore, we can rule out the possibility that <italic>Apc</italic>-deficient models are less sensitive to suppression of elongation as an explanation for the lack of effect with the <italic>Rpl24</italic> mutant presented here, when compared to the <italic>Apc</italic>-deficient <italic>Kras</italic>-mutant models. As suggested by the reviewers we have quantified proliferation in Apc<sup>fl/fl</sup>, Apc<sup>fl/fl</sup> Rpl24<sup>Bst/+</sup>, Apc<sup>fl/fl</sup> Eef2k<sup>D273A/D273A</sup> and Apc<sup>fl/fl</sup> Rpl24<sup>Bst/+</sup> Eef2k<sup>D273A/D273A</sup> intestines, to test the effect of Eef2K deletion in this <italic>Kras</italic> wild-type model (Figure 5 —figure supplement 1D). We see no difference in proliferation in either the small intestine or colons of these genotypes, consistent with neither the Rpl24<sup>Bst/+</sup> or Eef2k<sup>D273A/D273A</sup> alleles having any effect on proliferation or tumorigenesis in this setting.</p><p>We sought to supplement the data on ribosomal protein expression across the different tumour models by quantifying protein levels by Western blot. This was carried out for RPL24, RPL22 and RPS6 expression in lysates from wild-type, Apc<sup>fl/fl</sup> and Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup> organoids, shown in <xref ref-type="fig" rid="sa2fig1">Author response image 1</xref>. This revealed a truncated form of RPL24 that was the dominant isoform in the Apc<sup>fl/fl</sup> organoids, while the full-length version was dominant in wild-type and Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup> organoids. Investigating this truncation is part of our ongoing work, and we anticipate this will be linked to the differential effect on tumorigenesis in the <italic>Kras</italic> wild-type and mutant models. Truncated RPL24 has not been previously published but was the subject of a talk at the EMBL Protein Synthesis and Translation Control conference in September 2021. We feel that our data are too preliminary to include in this manuscript but are happy to present it here. The blots also show that RPL24 protein expression is not greatly increased in the Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup> organoids compared to Apc<sup>fl/fl</sup> organoids, in line with the RNAseq data in Figure 4F. In contrast, RPL22 and RPS6 show increased expression in the <italic>Kras</italic> mutant organoids. This is consistent with the model proposed that RPL24 levels become limiting in the Apc<sup>fl/(fl/+)</sup> Kras<sup>G12D/+</sup> models, due to a relatively modest increase in expression in <italic>Kras</italic> mutant cells compared to the other ribosomal proteins.</p><fig id="sa2fig1" position="float"><label>Author response image 1.</label><caption><title>A truncated form of RPL24 is expressed in Apc<sup>fl/fl</sup> but not Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup> organoids.</title><p>The significance of this in regulating tumorigenesis is currently under investigation. Fold changes in RP abundance from Apc<sup>fl/fl</sup> to Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup> are shown relative to β-actin. For RPL24 expression both isoforms were quantified together. Two exposures are shown for RPL24, short on top and longer below.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-69729-sa2-fig1-v1.tif"/></fig><disp-quote content-type="editor-comment"><p>2. The BrdU cell counting throughout the manuscript is normalised &quot;per half crypt&quot;. BrdU positive staining often goes beyond the crypts towards villi in Apc mutant and Apc/Kras mutant models. It is unclear how half crypt is defined in hyperproliferative crypts (such as Figure 2C) between genotypes.</p></disp-quote><p>The reviewer is correct that this designation could be misinterpreted. BrdU positivity was quantified for entire crypt/villus axes in all cases, negating the effects of hyperproliferation. Therefore, labelling has been corrected to read ‘per half crypt/villus’ throughout the figures, legends, and manuscript. A sentence has also been added to the Materials and methods, Mouse studies section clarifying the scoring method used, indicating that proliferation was scored from crypt base to villus tip.</p><disp-quote content-type="editor-comment"><p>3. In Figure 4B, the BrdU staining is clearly reduced in Apcfl/flRpl24Bst/+ compared to Apcfl/fl intestine, yet quantitation shows no difference. Again, this may depend on how &quot;BrdU<sup>+</sup> cells per half crypt&quot; is defined in different genotypes when there is massive crypt expansion in one but not the other.</p></disp-quote><p>The images shown in the original submission were difficult to interpret due to low intensity of the BrdU stain, specifically in the Apc<sup>fl/fl</sup> intestine image. This has been replaced with a better image from which it can be seen that the extent of crypt/villus proliferation is similar to the Apc<sup>fl/fl</sup> Rpl24<sup>Bst/+</sup> example. It is important to remember that staining of the intravillus stroma, which is outside the intestinal epithelium and thus not scored, can alter the appearance of the BrdU positive zone in these images.</p><disp-quote content-type="editor-comment"><p>4. In figure S1F, the authors show that mutated Rpl24 restricts irradiation-induced regeneration by quantifying regenerative crypts. How did the authors define &quot;regenerative crypt&quot; without staining? Also, how was the data normalised with all wildtype controls set at = 1?</p></disp-quote><p>Regenerating crypts were scored from the H and E stained slides as previously described (Faller et al., Nature, 2015. PMID: 25383520). <xref ref-type="fig" rid="sa2fig2">Author response image 2</xref> shows an example of regenerating crypts on an H and E slide at high magnification. The images in Figure 1 —figure supplement 2C have also been enlarged to help the reader interpret the regenerating crypts. With regards to the normalisation of the data, this is due to differences between the four batches of experiments that were performed. In each case <italic>Rpl24<sup>Bst</sup></italic> mutation suppressed regeneration but the baseline regeneration of the controls was varied. Thus, the number of regenerating crypts per circumference was normalised to the control mice for each batch. <xref ref-type="fig" rid="sa2fig2">Author response image 2</xref> shows the data before normalisation. Two sentences have been added to the Materials and methods clarifying this scoring technique.</p><fig id="sa2fig2" position="float"><label>Author response image 2.</label><caption><title>Left, example HandE staining of regenerative small intestine, showing two regenerating crypts with red arrows.</title><p>Right, regeneration data before batch normalisation. Colour coded circles show each of 4 batches in yellow (1v1), pink (1v1), blue (2v1) and red (1v1).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-69729-sa2-fig2-v1.tif"/></fig><disp-quote content-type="editor-comment"><p>5. The authors show that tumour numbers are not affected in Figure S2D and S5E. What about tumour size?</p></disp-quote><p>Tumour volumes have been added adjacent to both figures. These follow the same trend as the tumour size, showing no differences within each tumour model. Text has been added to the Results section to reference these graphs and a sentence added to the methods describing the calculation of tumour volumes from recorded diameters.</p><disp-quote content-type="editor-comment"><p>6. There are multiple figure citation errors in the manuscripts, particularly in result session including line 148-9/figure 1D, lines 243,244/figure4D, line 274/figureS2A, line 277/figure4D, line 279/figure4E and line 287/figureS4E. Please proofread.</p></disp-quote><p>We apologise for this and have now proofread and corrected these citation errors.</p><disp-quote content-type="editor-comment"><p>7. The authors claim that there are 75% increase in P-eEF2 and 50% reduction in RPL24 expression in Figure 1F. Where's the quantitation?</p></disp-quote><p>This quantification has now been added to the Western blot in Figure 1F in the form of raw values for each lane and a summary figure next to the values. The figure legend has also been altered to describe the additional data.</p><disp-quote content-type="editor-comment"><p>8. Please provide p-value for Figure 4B (H-score of Rpl24 and p-eEF2) and Figure S6B.</p></disp-quote><p><italic>P</italic> values have been added for Figure 4B – 0.05 for RPL24 and, after a larger batch of staining was performed, 0.048 for P-eEF2. <italic>P</italic> values have been added to Figure 6B, showing a significant increase in heavy polysome from Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup> to Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup> Rpl24<sup>Bst/+</sup> intestines but not from Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup> Rpl24<sup>Bst/+</sup>to Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup> Rpl24<sup>Bst/+</sup> Eef2k<sup>D273A/D273A</sup> intestines. This lack of significance has been clarified in the main text.</p><disp-quote content-type="editor-comment"><p>9. Questions remain around the mechanism of action of RPL24-bst. Does RPL24-bst really not alter ribosome abundance? How are the polysome profiles normalised? Are cell equivalents loaded? Could the ratio of different poly fractions be maintained +/- RPL24-bst but total number of ribosomes be reduced?</p></disp-quote><p>The polysome profiles are normalised internally, with differing amounts of input material loaded. This is due to the need for rapid sample handling to retain polysome integrity. In our experience, slow sample processing, such as counting cells or weighing tissue, leads to either RNA degradation or ribosome run-off. As such, we use the fact that all the ribosomes will be represented in each trace, as either sub-polysomes or polysomes, and then present data as ratios normalised within each gradient. These ratios are then compared between genotypes. i.e., the 60S:40S ratio and sub-polysome:polysome ratios are calculated with the data from each gradient replicate and will be unchanged by the overall quantity of material analysed. It is therefore true that we cannot use the gradient traces to exclude the possibility that different genotypes have different overall quantities of ribosomes. However, we provide evidence supporting broadly similar levels of ribosomes below.</p><disp-quote content-type="editor-comment"><p>10. What is the protein expression level of other RPLs when RPL24bst is expressed? This information for a few RPLs would either support the concept that ribosome number is maintained or would reveal a co-ordinated reduction in large ribosome subunit proteins.</p></disp-quote><p>We have quantified ribosomal protein abundances for RPL24, RPL10, RPL22 and RPS6 in Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup> and Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup> Rpl24<sup>Bst/+</sup> organoids, where equivalent total protein was loaded, and quantification normalised to β-actin protein expression. Here we saw increased expression of RPL10, reduced RPL22 and unchanged levels of RPS6 in the Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup> Rpl24<sup>Bst/+</sup> organoids compared to Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup> controls (Figure 3 —figure supplement 1E). This supports the conclusion that ribosome subunit abundance is not suppressed by mutation of Rpl24, and there is actually increased expression of RPL10. In the text we avoid making this statement regarding ribosome abundances. Instead, we refer to relative levels of the ribosomal subunits as a readout for ribosome biogenesis defects, as was previously reported for the Rpl24 mutant mouse (Oliver et al., Development, 2004. PMID: 15289434).</p><disp-quote content-type="editor-comment"><p>11. Does reduced RPL24 expression lead to ribosome heterogeneity? If ribosome number is unaltered, but one subunit, RPL24, is reduced, presumably there is ribosome heterogeneity? Would this lead to translational stress?</p></disp-quote><p>To address the ribosome heterogeneity question and whether RPL24 may be absent from some ribosomes we analysed the abundance of RPL24 protein within sucrose density gradients – shown as Figure 3 —figure supplement 2. This shows that in Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup> Rpl24<sup>Bst/+</sup> organoids, RPL24 protein was incorporated into 60S subunits, 80S ribosomes and polysomes. The distribution of RPL24 appears slightly altered towards polysomes, although this is not significant, with less RPL24 in the 60S subunit fraction. Data are presented as a percentage distribution of the total amount of each protein studied. It is therefore important to interpret this while considering the lower expression of RPL24 in the Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup> Rpl24<sup>Bst/+</sup> organoids, meaning that a modest reduction could actually be much greater. In contrast to the changes in RPL24 distribution, RPL10 expression is consistent between the two genotypes. We discuss these additional data in the text and how it may relate to ribosome heterogeneity. We respond to the question regarding translational stress below.</p><disp-quote content-type="editor-comment"><p>12. What is the mechanistic link between RPL24 and eEF2? Any hints at how eEF2 phosphorylation is influenced by RPL24? How direct is the mechanism? Is translational stress involved?</p></disp-quote><p>Elucidating this mechanism is part of ongoing work which we believe falls beyond the scope of this study. However, we do provide data focused on the phosphorylation dependent regulation of eEF2K in Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup> and Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup> Rpl24<sup>Bst/+</sup> organoids and tissue. eEF2K activity is regulated by mTORC1 and MEK signalling (inhibitory phosphorylation events) and AMPK (activation). We assayed the activity of these signalling pathways by measuring the phosphorylation of their canonical substrates, finding no differences between the two genotypes. This is shown in Figures 2 —figure supplement 2A (mTORC1) Figure 6 —figure supplement 2A (MEK) and Figure 6 —figure supplement 2B (AMPK). We discuss this data at length in the Results section and indicate that our ongoing work is searching for the mechanistic link.</p><p>The question regarding translation stress is an important one, and we have addressed by looking at the phosphorylation status of eIF2α across the models analysed in the manuscript. We saw that the Rpl24<sup>Bst</sup> mutation had no effect on P-eIF2α in otherwise wild-type mice (Figure 1 —figure supplement 1A-B), the Apc<sup>fl/fl</sup> Kras<sup>G12D/+</sup>model (Figure 2 —figure supplement 1A) or in the Apc<sup>fl/fl</sup> model (Figure 4 —figure supplement 2C). From this we conclude that translation stress signalling via eIF2α is not altered by mutation of <italic>Rpl24</italic>. In turn, this highlights the specificity in the regulation of eEF2K as a means to suppress protein synthesis in these mutant mice. These results are presented and discussed throughout the Results section, with the point regarding specificity of eEF2K regulation also mentioned.</p></body></sub-article></article>